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ABSTRACT 
Rewired biological pathways and/or rewired microRNA (miRNA)-mRNA interactions 
might also influence the activity of biological pathways. Here, rewired biological 
pathways is defined as differential (rewiring) effect of genes on the topology of biological 
pathways between controls and cases. Similarly, rewired miRNA-mRNA interactions are 
defined as the differential (rewiring) effects of miRNAs on the topology of biological 
pathways between controls and cases. In the dissertation, it is discussed that how 
rewired biological pathways (Chapter 1) and/or rewired miRNA-mRNA interactions 
(Chapter 2) aberrantly influence the activity of biological pathways and their association 
with disease. 
This dissertation proposes two PageRank-based analytical methods, Pathways of 
Topological Rank Analysis (PoTRA) and miR2Pathway, discussed in Chapter 1 and 
Chapter 2, respectively. PoTRA focuses on detecting pathways with an altered number of 
hub genes in corresponding pathways between two phenotypes. The basis for PoTRA is 
that the loss of connectivity is a common topological trait of cancer networks, as well as 
the prior knowledge that a normal biological network is a scale-free network whose 
degree distribution follows a power law where a small number of nodes are hubs and a 
large number of nodes are non-hubs. However, from normal to cancer, the process of the 
network losing connectivity might be the process of disrupting the scale-free structure of 
the network, namely, the number of hub genes might be altered in cancer compared to 
that in normal samples. Hence, it is hypothesized that if the number of hub genes is 
different in a pathway between normal and cancer, this pathway might be involved in 
cancer. MiR2Pathway focuses on quantifying the differential effects of miRNAs on the 
activity of a biological pathway when miRNA-mRNA connections are altered from 
ii 
 
normal to disease and rank disease risk of rewired miRNA-mediated biological 
pathways. This dissertation explores how rewired gene-gene interactions and rewired 
miRNA-mRNA interactions lead to aberrant activity of biological pathways, and rank 
pathways for their disease risk. The two methods proposed here can be used to 
complement existing genomics analysis methods to facilitate the study of biological 
mechanisms behind disease at the systems-level.  
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Chapter 1: INTRODUCTION 
1.1. Alteration in expression is associated with diseases 
It is well known that genomic alterations might lead to diseases. There have been many 
studies demonstrating it. For example, Hemophilia A and Huntington disease (HD) are 
monogenic diseases, which suggests that they might be caused by alteration of one gene. 
In addition to monogenic diseases, many other diseases might be caused by a 
combination of genomic alterations, epigenetic, miRNA-mediated, environmental and 
lifestyle factors, which are called complex diseases, such as diabetes, schizophrenia, or 
cancer. 
Several methods have been developed to identify active subnetworks from expression 
changes between two phenotypes. For example, Gene Set Enrichment Analysis (GSEA) is 
a well-known analytical method that determines whether a pre-defined set of genes 
shows statistically significant, concordant differences between two different phenotypes, 
which is also based on differential expression of a set of genes between two different 
phenotypes (Subramanian et al., 2005). 
Besides, there is another factor, miRNA, able to cause aberrant activity of genes, thereby 
be associated with diseases. MiRNAs are short non-coding RNAs of about 22 nucleotides 
in length, involved in the post-transcriptional regulation of gene expression. MiRNAs 
can induce the degradation of mRNA or translational repression of mRNA depending on 
the degree of homology to specific sequences, typically in the untranslated regions 
(UTRs) of their targets (Pasquinelli, 2012). MiRNAs can influence the expression of one 
or many genes at a time. It is reported that more than 60% of human genes are regulated 
by miRNAs (Friedman et al., 2009). Thus, miRNAs are regarded as key regulators of 
biological processes. That is to say, a single miRNA can control a biological process by 
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simultaneously targeting multiple genes of this specific biological process, and those 
targeted genes might be members of a cascade functioning towards a functional endpoint 
in the same biological pathways or in the crosstalk between biological processes (Lima et 
al., 2011). Over recent years, there are many studies demonstrating the role of miRNAs 
on controlling a wide variety of fundamental biological processes involved in 
proliferation, apoptosis, cell growth, differentiation, invasiveness, motility, and other 
oncogenic processes. For example, miRNA-21 can down-regulate the activity of the IL-
12/IFN-γ pathway in lung cancer (Lu et al., 2011). MiRNA-7 can influence activity of the 
PI3-kinase/Akt pathway in hepatocellular carcinoma and glioblastoma (Kefas et al., 
2008; Fang et al., 2012). MiRNA-200 is able to influence activity of E-cadherin and 
Wnt/β-catenin signaling pathways (Saydam et al., 2009). Based on those, several tools 
have been developed to detect miRNA-pathway associations (Nam et al., 2009; 
Maragkakis et al., 2011; Hsu et al., 2011a; Lu et al., 2012; Ben-Hamo & Efroni, 2015; 
Godard & van Eyll, 2015; Preusse, Theis & Mueller, 2016; Backes et al., 2016; Han et al., 
2016; Backes et al., 2017). 
Indeed, differential gene expression level in biological network might influence 
phenotypes. However, only investigating the differential expression levels of gene may be 
not sufficient since the topology of biological pathway is also an important characteristic 
of biological pathways and the role they play in both normal and pathological processes, 
as described below. 
 
1.2. Alteration in topology is associated with diseases 
Each biological pathway exerts its function by delivering signaling through the gene 
network. Theoretically, a pathway is supposed to have a robust topological structure 
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under normal physiological conditions. However, the pathway’s topological structure 
could be altered under some pathological condition. It is well known that a normal 
biological network is a scale-free network whose degree distribution follows a power law 
where a small number of nodes are hubs and a large number of nodes are non-hubs. In 
addition, it is reported that the loss of connectivity is a common topological trait of 
cancer networks. Hence, from normal to cancer, the process of the network losing 
connectivity might be the process of disrupting the scale-free structure of the network, 
namely, the number of hub genes might be altered in cancer compared to that in normal. 
Based on this, we propose a new PageRank-based method called Pathways of Topological 
Rank Analysis (PoTRA) to detect pathways involved in cancer.  
Recent studies have shown miRNAs as key regulators of a wide variety of biological 
processes, such as proliferation, differentiation, apoptosis, metabolism, etc. Rewired 
miRNA-mRNA connections can influence the activity of biological pathways, because 
miRNA-mRNA connections tend to be dynamic or condition-specific, or differential 
between disease and non-disease. Here, we define rewired miRNA-mRNA connections 
as the differential (rewiring) effects on the activity of biological pathways between 
diseased and normal phenotypes. Chapter 3 proposes a PageRank-based method to 
measure the degree of miRNA-mediated dysregulation of biological pathways between 
HCC and normal samples based on rewired miRNA-mRNA connections. The degree of 
miRNA-mediated dysregulation of biological pathways is regarded as disease risk of 
biological pathways by measuring total differential influence of all miRNAs on the 
activity of a pathways between diseased and normal conditions, thereby I can rank 
biological pathways for disease risk. 
 
1.3. Google search algorithm: PageRank 
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Chapter 2 and Chapter 3 propose two methods, PoTRA and miR2Pathway, which are 
based on PageRank. The PageRank algorithm is used by the Google search engine to 
rank the importance of web pages, which is based on the assumption that the importance 
of a web page is high in a network if this web page has connections with other nodes of 
high importance. This idea is naturally applied to analyzing biological networks, where 
the importance of a gene is high if this gene is connected to other genes of high 
importance. In our study, the gene-gene network is an undirected graph where a node 
represents a gene and the edges can be defined by prior knowledge (e.g., KEGG 
database). 
The output from the PageRank algorithm is a probability distribution representing the 
likelihood that a person randomly clicking on links will arrive at any particular web page. 
A probability is a numeric value between 0 and 1. The sum of probabilities for all web 
pages is equal to 1. The probability of a web page is proportional with the time spent at 
the web page when a person surfs the web. This idea can also be intuitively extended to 
ranking genes in gene networks where the probability of a gene is proportional with the 
time a research scientist spends looking and returning at the same gene when analyzing 
research results. For additional details of PageRank, please refer to (Page et al., 1999). 
 
1.4. Summary 
In summary, rewired gene-gene interactions and miRNA-mRNA interactions might 
cause aberrant activity of biological pathways. Chapter 2 focuses on how rewired gene-
gene interactions lead to aberrant activity of biological pathways, and Chapter 3 focuses 
on how rewired miRNA-mRNA interactions lead to aberrant activity of biological 
pathways. In Chapter 2, each biological pathway exerts its function by delivering 
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signaling through the gene network. Theoretically, a pathway is supposed to have a 
robust topological structure under normal physiological conditions. However, the 
pathway’s topological structure could be altered under some pathological condition. It is 
well known that a normal biological network is a scale-free network whose degree 
distribution follows a power law where a small number of nodes are hubs and a large 
number of nodes are non-hubs. In addition, it is reported that the loss of connectivity is a 
common topological trait of cancer networks. Hence, from normal to cancer, the process 
of the network losing connectivity might be the process of disrupting the scale-free 
structure of the network, namely, the number of hub genes might be altered in cancer 
compared to that in normal. Based on this, we propose a new PageRank-based method 
called Pathways of Topological Rank Analysis (PoTRA) to detect pathways involved in 
cancer. We use PageRank to measure the relative topological ranks of genes in each 
biological pathway, then select hub genes for each pathway, and use Fisher’s exact test to 
test if the number of hub genes in each pathway is altered from normal to cancer. We 
apply PoTRA to study hepatocellular carcinoma (HCC) and several subtypes of HCC. In 
Chapter 3, I present a PageRank-based method, called miR2Pathway, to measure the 
degree of miRNA-mediated dysregulation of biological pathways between HCC and 
normal sample based on rewired miRNA-mRNA connections. miR2Pathway proposed 
here systematically shows the first evidence for a mechanism of biological pathways 
dysregulated by rewired miRNA-mRNA connections,  
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Chapter 2: Pathways of Topological Rank Analysis (PoTRA): A Novel Method 
to Detect Pathways Involved in Cancer 
 
2.1. Introduction 
High throughput technologies, such as genomic sequencing and microarrays, allow the 
genome-wide analysis of molecular factors associated with disease. While the 
technologies have advanced and have been refined to generate an increasing amount of 
high quality data, challenges remain in understanding the biological processes involved 
in disease etiology, particularly for complex disorders.   
As we know, individual genomic alterations may result in diseases. For example, 
Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency in the 
activity of coagulation factor VIII (Franchini & Mannucci, 2012). Huntington disease 
(HD) is an autosomal dominant progressive neurodegenerative disorder with a distinct 
phenotype characterized by chorea, dystonia, incoordination, cognitive decline, and 
behavioral difficulties, which is caused by a heterozygous expanded trinucleotide repeat 
(CAG)n, encoding glutamine, in the gene encoding huntingtin (HTT) on chromosome 
4p16 (Walker, 2007; Dayalu & Albin, 2015). 
In addition to  monogenic diseases, many diseases are complex, such as diabetes, 
schizophrenia, or cancer, and are believed to be caused by a combination of genomic 
alterations, epigenetic, environmental and lifestyle factors (Schork, 1997; Hindorff, 
Gillanders & Manolio, 2011). Genomic disease association analysis suggests that complex 
diseases are not caused by individual genomic alterations. First, the complex disease 
phenotype is associated with many genes. Second, it may be associated with interactions 
among many genes. Therefore, more and more literature has been focusing on analyzing 
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sets of genes associated with some phenotype. Gene expression profiles have been used 
to assess the activity of biological networks. Several approaches have been developed to 
identify active subnetworks across different phenotypes from changes in gene 
expression. One of the first such studies is a general approach to searching for “active 
sub-networks” associated with high levels of differential expression (Ideker et al., 2002). 
This approach identifies a set of genes that form a subnetwork whose expression is 
altered across two different phenotypes. Another very well-known method, Gene Set 
Enrichment Analysis (GSEA) (Subramanian et al., 2005), is a computational method 
that determines whether a pre-defined set of genes shows statistically significant, 
concordant differences between two phenotypes, which is also based on differential 
expression of a set of genes between two phenotypes. These approaches, while powerful 
and popular, are limited by the fact that they ignore the topology of the gene networks 
and sets that they investigate. Indeed, differential gene expression level in biological 
network might influence phenotypes. However, only investigating the differential 
expression levels of gene may be not sufficient since the topology of biological pathway is 
also an important characteristic of biological pathways and the role they play in both 
normal and pathological processes, as described below.  
It is well known that the topological structure is very important for biological networks 
and it determines how genes interact with each other, governing how specific genes and 
biological pathways operate in the promotion or inhibition of human diseases (Tavazoie 
et al., 1999; Goeman & Bühlmann, 2007; Tarca et al., 2009; Taylor et al., 2009; Khatri, 
Sirota & Butte, 2012; Rhinn et al., 2013; Mitrea et al., 2013). Related to this, a hub gene 
within a biological network is an important gene which acts to influence the activity of a 
number of genes (Flintoft, 2004), even influence the activity and function of the entire 
biological network. Hence, there has been an increased interest to analyze the co-
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regulation and co-expression of genes in the biological network, and many approaches 
have been developed to identify differential co-regulation and co-expression of genes in 
the subnetwork (Kostka & Spang, 2004; Lai et al., 2004; Reverter et al., 2006; Watson, 
2006; Choi & Kendziorski, 2009; Leonardson et al., 2010; Langfelder et al., 2011; Odibat 
& Reddy, 2012).  It has been a trend to extend differential expression analysis to 
differential network analysis (de la Fuente, 2010).  
Most of the approaches for differential network analysis are based on different 
correlation-based metrics to measure the strength of association between any pairs of 
nodes in a biological network. Generally, there are three main ways to compare networks 
for differential network analysis. The first approach handles weighted networks and uses 
some functions of the edge-specific weight differences as edge weights to construct 
differential networks (Hudson, Reverter & Dalrymple, 2009; Tesson, Breitling & Jansen, 
2010; Liu et al., 2010; Rhinn et al., 2013). The second approach tries to find co-
expressed gene sets and identify which correlation patterns are different between sets 
across conditions (Watson, 2006; Rahmatallah, Emmert-Streib & Glazko, 2014). This 
approach formulates summary measures that represent co-expression in a biological 
network and compares the metric between sets. The third approach compares the 
topology of biological networks across different phenotypes by using measures such as 
degree of nodes or modularity (Reverter et al., 2006; Zhang et al., 2009).  
Although the above methods for differential network analysis can deal with some 
important biological questions, they are still limited. In general, they are based on a basic 
hypothesis that some connections between genes across the groups could be thought of 
as “passenger” events and other connections are unique to either one of groups and thus 
could be “driver” events that contribute to disease progression and development. Hence, 
they focus on the contribution of individual differential connections to disease. This 
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results in several limitations. First, each differential connection is regarded by these 
methods to have an equal contribution to disease. However, it is well understood that 
loss of a connection between two hub genes from normal to disease is more deleterious 
than loss of a connection between two non-hub genes. Second, how differential 
connections (“driver” connections mentioned above) between pairs of genes are 
associated with diseases is still not very biologically intuitive, because how the 
dependency between genes contributes to diseases is usually little understood. 
To address these problems, we propose a new PageRank-based method called Pathways 
of Topological Rank Analysis (PoTRA) to detect pathways associated with cancer. 
PageRank is an algorithm initially used by Google Search to rank websites in their search 
engine results (Page et al., 1999). It is a way of measuring the importance of nodes in a 
network. More generally, PageRank has been applied to other networks, e.g., social 
networks (Pedroche et al., 2013; Wang et al., 2013). To date, there have been several 
studies using PageRank for gene expression and network analysis (Morrison et al., 2005; 
Winter et al., 2012; Kimmel & Visweswaran, 2013; Hou & Ma, 2014; Bourdakou, 
Athanasiadis & Spyrou, 2016; Zeng et al., 2016; Ramsahai et al., 2017). . These studies 
focus on ranking genes and discovering key driver genes in disease, and do not try to 
detect dysregulated pathways involved in disease. Other studies (Winter et al., 2012; 
Zeng et al., 2016) use PageRank to select topological important genes and simply see 
which pathways that these topological important genes are involved in. These PageRank-
related approaches are very different from our approach.  
Our approach embodied by PoTRA is motivated by the observation that the loss of 
connectivity is a common topological trait of cancer networks (Anglani et al., 2014), as 
well as the prior knowledge that a normal biological network is a scale-free network 
whose degree distribution follows a power law where a small number of nodes are hubs 
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and a large number of nodes are non-hubs (Albert, 2005; Khanin & Wit, 2006; Zhu, 
Gerstein & Snyder, 2007). However, from normal to cancer, the process of the network 
losing connectivity might be the process of disrupting the scale-free structure of the 
network, namely, the number of hub genes might be altered in cancer compared to that 
in normal samples. Thus, we hypothesize that if the number of hub genes is different in a 
pathway between normal and cancer, this pathway might be involved in cancer. Based on 
this hypothesis, we propose to detect pathways involved in cancer by testing if the 
number of hub genes for each pathway is different between normal and cancer samples. 
Therefore, the PoTRA approach computes topological ranks of genes in each pathway, 
and then detects pathways with significantly altered number of hub genes between 
normal and cancer. Namely, we first use the Google search PageRank algorithm to 
measure the relative topological ranks of genes in a biological pathway across different 
conditions. Then, we use Fisher’s exact test to estimate if the number of hub genes in 
each pathway is significantly different between normal and cancer. As an illustration, we 
apply PoTRA to study hepatocellular carcinoma (HCC) and its subtypes and identify 
disease-relevant pathways. In conclusion, PoTRA is a new approach to explore and 
discover cancer-associated pathways. PoTRA can be used as a complement to other 
existing methods to enrich our understanding of the biological mechanisms behind 
cancer at the systems-level. 
 
2.2. Materials and Methods 
Overview of the PoTRA method 
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Figure 2.1. Overview of the PoTRA method. 
Below we detail the steps of the PoTRA method, as illustrated in Figure 2.1. 
 
2.2.1. Data  
To illustrate the PoTRA method, we use publicly available gene expression datasets from 
The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) hepatocellular 
carcinoma (HCC) study. We analyze and contrast 50 HCC samples and 50 tumor-
adjacent normal samples (“normal samples” in future sections). In addition, the datasets 
also include gene expression profiles for several HCC subtypes. We further analyze and 
contrast 22 hepatitis B-induced HCC samples and 22 tumor-adjacent normal samples, 
34 hepatitis C-induced HCC samples and 34 tumor-adjacent normal samples, and 50 
alcohol-induced HCC samples and 50 tumor-adjacent normal samples. There are 20,531 
gene expression values for each sample. Pathway information from the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa & Goto, 2000) is used. 
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To date, there is much known about etiology of HCC (Beasley, 1988; Sanyal, Yoon & 
Lencioni, 2010; Wang et al., 2012; Goossens & Hoshida, 2015) and knowledge of 
pathways involved in HCC (Villanueva et al., 2008; Zhou et al., 2010; Wang et al., 2017), 
which makes it easier to illustrate and assess the PoTRA method. 
 
2.2.2. Construction of gene co-expression network for a pathway 
We apply the PoTRA method to gene expression profiles for several phenotypes, such as 
normal and cancer and cancer subtypes. First, we select genes for each pathway, using 
pathway information from KEGG. For each pathway, we determine the gene-gene 
interactions by using the Pearson’s correlation to test each co-expressed gene pair. The 
test calculates a P-value for the association between each pair of genes. A significance 
threshold of 0.05 is used. When the P-value of a pair of genes is below 0.05, we establish 
an edge between the corresponding two genes; otherwise, there is no edge between them. 
We implement it through a built-in function called “cor.test()” in the statistical software 
package R (https://www.r-project.org/). In this way, we can construct gene co-
expression networks (i.e., pathways) for normal and cancer, separately. Of note, all the 
gene co-expression networks (i.e., pathways) used by PoTRA are undirected graphs, 
because co-expression networks only focus on gene pairs with a similar expression 
pattern across samples, in other words, the transcript levels of two co-expressed genes 
rise and fall together across samples. 
 
2.2.3. PageRank analysis for genes within a pathway for normal and cancer 
Based on the above constructed interactions within a pathway, we can observe that some 
genes are hub genes whereas others are non-hub genes. We apply the PageRank 
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algorithm (Page et al., 1999) to obtain the corresponding topological importance for each 
gene within the pathway for normal and cancer, separately, see Figure 2.2.                  
                                   
 
Figure 2.2. The topological rank analysis for each gene within a pathway. For 
genes within a specified pathway, according to Step 2, we construct a corresponding 
gene co-expression network for normal and cancer, separately. Then we apply the 
PageRank method to obtain the topological importance of each gene for normal and 
cancer, separately. PR(gene i)normal represents the PageRank score of the gene i for 
normal samples, while PR(gene i)cancer represents the PageRank score of the gene i for 
cancer samples. 
We implement it by using the page.rank() function from the igraph (Csárdi & Nepusz, 
2006) R package. As mentioned in Step 2, all the networks that we construct are 
undirected graphs. Thus, the PageRank algorithm used in our approach is based on 
undirected graphs.  
 
2.2.4. Detect pathways with significantly altered number of hub genes 
between normal and cancer using Fisher’s exact test 
As mentioned above, PoTRA is motivated by the observation that the loss of connectivity 
is a common topological trait of cancer networks (Anglani et al., 2014) and the prior 
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knowledge that a normal biological network is a scale-free network whose degree 
distribution follows a power law where a small number of nodes are hubs and a large 
number of nodes are non-hubs (Albert, 2005; Khanin & Wit, 2006; Zhu, Gerstein & 
Snyder, 2007). From normal to cancer, the process of the network losing connectivity 
might be the process of disrupting the scale-free structure of the network, which can 
result in an altered number of hub genes between normal and cancer. Hence, a statistics 
that we compare between two phenotypes is the number of hub genes. The PageRank 
scores of all genes of a pathway form a distribution, and we use the 95th percentile of the 
distribution (one-tail) in normal samples as cutoff value for hub genes for both normal 
and cancer samples. The genes in this pathway with PageRank scores that are above the 
cutoff value are identified as hub genes for this pathway. Then we count the number of 
hub genes for normal and cancer, separately. Next, we use Fisher’s exact test to assess if 
the number of hub genes is significantly different between normal and cancer. For 
details, see Table 2.1. 
 
The number of non-
hub genes 
The number of hub 
genes Row total 
Normal a b a+b 
Cancer c d c+d 
Column total a+c b+d a+b+c+d 
Table 2.1. The contingency table for Fisher’s exact test. We use the 95th 
percentile of the distribution (one-tail) in normal samples as cutoff value for hub genes 
for both normal and cancer samples. The value “a” represents the number of genes whose 
PageRank scores are below the cutoff value for normal samples. The value “b” represents 
the number of genes whose PageRank scores are above the cutoff value for normal 
samples. The values “c” and “d” are the corresponding values for cancer. We use Fisher’s 
exact test to assess if the number of hub genes is significantly different between normal 
and cancer. 
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Fisher’s exact test estimates the probability of obtaining any such set of values, given by 
the hypergeometric distribution:                                                              
                                P= 
(
𝒂+𝒃
𝒂
)(
𝒄+𝒅
𝒄
)
(
𝒏
𝒂+𝒄
)
 = 
(𝒂+𝒃)!(𝒄+𝒅)!(𝒂+𝒄)!(𝒃+𝒅)!
𝒂!𝒃!𝒄!𝒏!
                           (1) 
Where n=a+b+c+d, and (𝑖
𝑗
) is the binomial coefficient and the symbol “!” indicates the 
factorial operator.  
Formula 1 gives the exact hypergeometric probability of observing this particular 
arrangement of the data, assuming the given marginal totals, on the null hypothesis that 
the number of hub genes is the same for a specified pathway between normal and cancer. 
If this test statistic is significant, it indicates that there is a significantly different number 
of hub genes between normal and cancer, thereby this pathway might be involved in 
cancer. By studying many pathways from the KEGG database we generate a multiple 
hypothesis testing problem. We address this issue by correcting the P-values calculated 
for each pathway using the False Discovery Rate (FDR) approach, using the Benjamini 
and Hochberg procedure (Benjamini & Hochberg, 1995) 
 
2.2.5.  Software tools 
All the analysis is conducted using the R statistical programming language, using the 
following R Biocoductor packages: graphite for pathway databases, igraph for PageRank 
function and graph for visualization.  
 
2.3.  Results 
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We apply PoTRA to analyze and contrast 50 HCC samples and 50 tumor-adjacent 
normal samples. All data come from The Cancer Genome Atlas (TCGA) hepatocellular 
carcinoma (HCC) study. 
 
2.3.1. PoTRA for HCC vs. normal samples 
To illustrate the PoTRA method, we use a cancer-associated pathway, “Pathways in 
cancer”, as an example in the following section.  
 
2.3.2. Construction of a gene co-expression network for a pathway 
As suggested before, “Pathways in cancer” might be comprised of different interactions 
between genes under different conditions, such as normal versus cancer conditions. 
First, we need to find the genes that this pathway consists of by using the KEGG 
database. In practice, we implement it by using an R package called graphite. Second, for 
the genes of this pathway, we identify the interactions between genes for normal and 
cancer samples, separately, see Figure 2.3.   
 
a. b.  
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Figure 2.3. Construction of “Pathways in cancer” co-expression network for 
normal and cancer samples, separately. There are 310 genes in this pathway, 
labeled 1-310.  For the gene names, see Table 2.7. Graph (a) represents the network for 
normal samples and graph (b) represents that for cancer samples. There are 24,924 
edges in graph (a) and 9,136 edges in graph (b). The red nodes represent hub genes. 
There are 16 hub genes in graph (a) and 48 hub genes in graph (b). 
 
Very interestingly, we find a large loss of connectivity in the cancer gene co-expression 
network with respect to normal ones, from 24,924 to 9,136 edges, which is also noticed 
by prior literature that has found that the loss of connectivity is a common topological 
trait of cancer networks (Anglani et al., 2014).   
 
2.3.3. PageRank analysis for genes within a pathway for normal and cancer 
Based on the interactions identified in the previous section, and illustrated in Figure 
2.3 (a) and (b), we can obtain a PageRank score for each gene in “Pathways in cancer” 
for normal and cancer, separately, which quantifies the influence of a gene on the activity 
of other genes in this pathway. For the results for this step, 2 vectors with 310 PageRank 
values, one for normal and one for cancer, separately, see Table 2.7.  As previously 
mentioned, the PageRank values in each vector add up to 1.  
As an interesting note, in Figure 2.3, gene 47 (top of Figure 2.3(a)) is an isolated gene 
in the pathway for normal, but the PageRank score of this gene is not zero, because zero 
is not allowed for PageRank calculation. Considering this situation, PageRank designs a 
damping factor p (typically p=0.85) and assigns a small number to this isolated node to 
solve this issue, for details see (Page et al., 1999).  
Figure 2.4 illustrates the distributions of PageRank scores for genes in “Pathways in 
cancer” for normal and cancer, separately.  
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Figure 2.4. The kernel density distribution of PageRank scores of genes in 
“Pathways in cancer”. The red line shows the kernel density distribution of PageRank 
scores for cancer and the black one is for normal samples. Note that the mean for the two 
distributions is the same, i.e., mean = 1/N=0.0032258, where N = 310 is the number of 
genes in the “Pathways in cancer” pathway. We use the 95th-percentile cutoff (= 
0.00482) of the kernel distribution in normal samples as cutoff for hub genes for both 
normal and cancer samples.   
 
Very interestingly, as connectivity is lost in cancer samples, the number of hub genes 
changes. While there are only 16, strongly-connected (with more edges, an average of 
148 edges) hub genes in the normal samples, there are 48 hub genes in the cancer 
samples, more loosely-connected (with fewer edges, an average of 104 edges).  
As mentioned before, the process of the network losing connectivity might be the process 
of disrupting the scale-free structure of the network whose degree distribution follows a 
power law where a small number of nodes are hubs and a large number of nodes are 
non-hubs, namely, the number of hub genes might be altered in cancer compared to that 
in normal. The altered number of hub genes might be a trait of a pathway in cancer, 
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which suggests the pathway is involved in cancer if the change in hub gene number is 
statistically significant.  
 
2.3.4. Fisher’s exact test for comparing the number of hub genes in the 
pathway 
We next use Fisher’s exact test to test if the number of hub genes for “Pathways in 
cancer” is significantly different between normal and cancer. The result for the 
“Pathways in cancer” pathway is included in Table 2.2. 
 
Gene 
Count(L) 
# of 
edges_norm
al 
# of 
edges_cance
r 
# of hub 
genes_norma
l 
# of hub 
genes_cancer 
Adjusted 
P-value 
Pathways 
in cancer 310 24924 9136 16 48 0.008 
Table 2.2. The “Pathways in cancer” pathway identified by PoTRA for HCC 
using Fisher’s exact test. The P value is adjusted by False Discovery Rate (FDR).  
 
The low P-value in Table 2.2 indicates that the number of hub genes in cancer samples 
is significantly different from that in normal samples, suggesting that the “Pathways in 
cancer” pathway is involved in HCC. This example suggests that a normal biological 
network is a scale-free network whose degree distribution follows a power law where a 
small number of nodes are hubs and a large number of nodes are non-hubs. Moreover, 
the loss of connectivity from normal to cancer might lead to disrupting the scale-free 
structure of the network in cancer, thereby resulting in the fact that the number of hub 
genes is altered in cancer compared to that in normal. 
Then we apply the same approach to other pathways from KEGG to compare HCC vs. 
normal samples. The significant pathways are shown in Table 2.3.  
20 
 
  
Gene  
Count(L) 
# of  
edges
_ 
norma
l 
# of  
edges
_ 
cancer 
# of 
hub  
genes_ 
normal 
# of 
hub  
genes_ 
cancer 
Adjusted  
P-value 
1 Pathways in cancer 310 24924 9136 16 48 0.0081 
2 MAPK signaling pathway 252 14005 5170 13 40 0.0158 
3 Breast cancer 143 3589 1175 8 29 0.0278 
Table 2.3. The significant KEGG pathways identified by PoTRA for HCC 
using Fisher’s exact test. FDR adjusted P-values are below 0.05. 
 
We find three significant pathways with altered number of hub genes between normal 
and cancer. It is well known that these three pathways are strongly associated with 
cancer in general. MAPK signaling pathway plays a role in the regulation of gene 
expression, cellular growth, and survival (Knight & Irving, 2014). Abnormal MAPK 
signaling might lead to uncontrolled or increased cell proliferation and resistance to 
apoptosis (Santarpia, Lippman & El-Naggar, 2012; Burotto et al., 2014). Interestingly, 
we also find that loss of connectivity and the larger number of hub genes for cancer are 
characteristics of the other two pathways as well.  
 
2.3.5. PoTRA for cancer subtype analysis 
Many complex diseases have subtypes and/or can be classified into different categories 
based on diagnosis, pathology, phenotype characteristics, etc. To further assess the 
PoTRA method, we apply it to several subtypes of the HCC TCGA data. There are several 
risk factors associated with HCC, such as hepatitis B, hepatitis C and alcohol (Beasley, 
1988; Sanyal, Yoon & Lencioni, 2010; Hoshida et al., 2014; Goossens & Hoshida, 2015). 
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Here, we apply PoTRA to compare these three subtypes of HCC samples with normal 
samples.  
Table 2.4 illustrates the Fisher’s exact test results for comparing normal with hepatitis 
B-induced HCC samples.  
  
Gene 
Count(L) 
# of 
edges_ 
normal 
# of 
edges_ 
cancer 
# of hub 
genes_ 
normal 
# of hub 
genes_ 
cancer 
Adjusted  
P-value 
1 
Insulin signaling 
pathway 139 2692 958 7 34 0.0007 
2 Pathways in cancer 310 11194 3792 16 52 0.0007 
3 
Hippo signaling 
pathway 151 2836 970 8 31 0.0072 
4 HTLV-I infection 194 5518 2080 10 35 0.0072 
5 
Neurotrophin 
signaling pathway 117 2441 895 6 25 0.0195 
6 
mTOR signaling 
pathway 144 3410 832 8 28 0.0240 
7 
Epstein-Barr virus 
infection 85 1524 435 5 21 0.0353 
8 Hepatitis B 134 2708 828 7 25 0.0353 
Table 2.4. The significant KEGG pathways identified by PoTRA for hepatitis 
B-induced HCC using Fisher’s exact test. FDR adjusted P-values are below 0.05. 
 
There is one common pathway, Pathways in cancer, between Table 2.4 and Table 2.3. 
There are seven other new pathways, which are very interesting and associated with the 
hepatitis B-induced HCC. First, the “Hepatitis B” pathway is detected by our method. 
Hepatitis B is the most important and direct factor causing hepatitis B-induced HCC. In 
addition, we find two other pathways, HTLV-I (Human T-cell leukemia virus type I) 
infection and Epstein-Barr virus infection, which are strongly associated with virus 
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infection and cancer. This is consistent with the viral pathology of hepatitis B-induced 
HCC. Besides, some studies show that hepatitis B virus infection can contribute to the 
impairment of insulin signaling, which is another pathway identified by PoTRA (Kim, 
Kim & Cheong, 2010; Barthel et al., 2016). Finally, the other three pathways, Hippo 
signaling pathway, Neurotrophin signaling pathway and mTOR signaling pathway are 
associated with cancer in general. Hippo signaling pathway is reported to be able to 
control organ size through regulating cell proliferation and apoptosis (Saucedo & Edgar, 
2007; Pan, 2010). It is reported that neurotrophins can regulate cancer stem cells 
(Chopin et al., 2016), and neurotrophins contribute to pro-survival signaling in many 
different types of cancer (Molloy, Read & Gorman, 2011). mTOR signaling pathway is a 
well-known cancer-associated pathway. Alterations of mTOR signaling pathway have 
significant effects on cancer progression. The major components of mTOR signaling 
pathway are critical effectors in cell signaling pathways commonly deregulated in 
cancers (Guertin & Sabatini, 2007; Villanueva et al., 2008; Pópulo, Lopes & Soares, 
2012).  
These results suggest that PoTRA can be used to identify not only the pathways 
associated with cancer in general, but also those pathways associated with cancer 
subtypes, such as hepatitis B-induced HCC specifically.  
Results of the PoTRA analysis from two other HCC subtypes, hepatitis C-induced HCC 
and alcohol-induced HCC, are included in Table 2.5 and Table 2.6, respectively. 
  
Gene 
Count(L) 
# of 
edges_ 
normal 
# of 
edges_ 
cancer 
# of hub 
genes_ 
normal 
# of hub 
genes_ 
cancer 
Adjusted  
P-value 
1 Pathways in cancer 310 22253 7791 16 62 
2.89E-
06 
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2 
PI3K-Akt signaling 
pathway 340 19901 6594 17 65 
2.89E-
06 
3 
MAPK signaling 
pathway 252 11986 4168 13 47 0.0003 
4 Proteoglycans in cancer 204 9815 3642 11 38 0.0033 
5 Rap1 signaling pathway 208 8294 3587 11 34 0.0215 
6 
Adrenergic signaling in 
cardiomyocytes 149 3594 1355 8 27 0.0372 
7 cAMP signaling pathway 196 5106 2493 10 30 0.0372 
8 Focal adhesion 203 10225 4656 11 32 0.0372 
9 HTLV-I infection 194 9843 4030 10 30 0.0372 
10 Ras signaling pathway 226 10098 3931 12 33 0.0376 
11 FoxO signaling pathway 126 3391 1222 7 24 0.0380 
12 
Osteoclast 
differentiation 123 4418 1452 7 24 0.0380 
13 ErbB signaling pathway 88 2128 814 5 20 0.0400 
14 Axon guidance 167 6203 2705 9 27 0.0433 
Table 2.5. The significant KEGG pathways identified by PoTRA for hepatitis 
C-induced HCC using Fisher’s exact test. FDR adjusted P-values are below 0.05. 
 
In Table 2.5, we find two common pathways, Pathways in cancer and MAPK signaling 
pathway, between Table 2.5 and Table 2.3. Among the other pathways, we find several 
pathways related to cancer generally and hepatitis C-induced HCC specifically. First, 
HTLV-I infection is also listed in this table, and, as mentioned above, is associated with 
virus infection and cancer.  Almost all other pathways are associated with cancer in 
general. PI3K-Akt signaling pathway is a key regulator of normal cellular processes 
involved in cell growth, proliferation, motility, survival, and apoptosis (Porta, Paglino & 
Mosca, 2014). The Proteoglycans in cancer pathway is involved in regulation of 
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proteoglycans, heavily glycosylated proteins present especially in connective tissue in 
cancer. Rap1 signaling pathway is reported to be involved in cancer cell migration, 
invasion and metastasis (Bailey, 2009; Zhang et al., 2017). The cAMP signaling pathway 
regulates a number of biological processes, such as cell growth and adhesion, neuronal 
signaling, energy homeostasis and muscle relaxation (Fajardo, Piazza & Tinsley, 2014). 
The key component of Focal adhesion pathway, Focal adhesion kinase (FAK), is reported 
to enable activation by growth factor receptors or integrins in different types of cancers. 
FAK is an important mediator of cell proliferation, cell migration, cell growth 
(Golubovskaya, Kweh & Cance, 2009; Tai, Chen & Shen, 2015). A large volume of 
literature shows Ras signaling pathway is involved in several aspects of normal cell 
growth and malignant transformation, and plays an important role in cancer 
development and progression (Vojtek & Der, 1998; Downward, 2003; Santarpia, 
Lippman & El-Naggar, 2012; Knight & Irving, 2014). FoxO signaling pathway is involved 
in the regulation of the cell cycle, apoptosis and metabolism (Schmidt et al., 2002; Fu & 
Tindall, 2008; Gross, van den Heuvel & Birnbaum, 2008). Besides, activity of FoxO 
signaling pathway also affects stem cell maintenance and lifespan (Eijkelenboom & 
Burgering, 2013). ErbB signaling pathway plays roles in cancer development and 
progression (Hynes & Lane, 2005; Seshacharyulu et al., 2012), as well as in cancer cell 
migration and invasion (Appert-Collin et al., 2015). ErbB signaling pathway is associated 
with the development of a wide variety of types of solid tumor if ErbB signaling is 
excessive (Cho & Leahy, 2002). The Axon guidance pathway is also reported to regulate 
cell migration and apoptosis, and be associated with tumorigenesis (Chédotal, Kerjan & 
Moreau-Fauvarque, 2005).  
25 
 
  
Gene 
Count(L) 
# of 
edges_ 
normal 
# of 
edges_ 
cancer 
# of hub 
genes_ 
normal 
# of hub 
genes_ 
cancer 
Adjusted  
P-value 
1 
PI3K-Akt signaling 
pathway 340 23928 8733 17 55 0.0006 
2 
MAPK signaling 
pathway 252 14005 5767 13 46 0.0007 
3 Pathways in cancer 310 24924 10191 16 47 0.0043 
Table 2.6. The significant KEGG pathways identified by PoTRA for alcohol-
induced HCC using Fisher’s exact test. FDR adjusted P-values are below 0.05. 
 
We find two common pathways between Table 2.6 and Table 2.3, MAPK signaling 
pathway and Pathways in cancer. As mentioned above, PI3K-Akt signaling pathway also 
plays an important role in cancer (Porta, Paglino & Mosca, 2014). 
 
2.4.  Discussion 
We propose a PageRank-based method, Pathway of Topological Rank Analysis (PoTRA), 
for identifying pathways involved in cancer. PoTRA is motivated by the observation that 
the loss of connectivity is a common topological trait of cancer networks (Anglani et al., 
2014) and the prior knowledge that a normal biological network is a scale-free network 
whose degree distribution follows a power law where a small number of nodes are hubs 
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and a large number of nodes are non-hubs (Albert, 2005; Khanin & Wit, 2006; Zhu, 
Gerstein & Snyder, 2007). From normal to cancer, the process of the network losing 
connectivity might be the process of disrupting the scale-free structure of the network, 
which can result in an altered number of hub genes between normal and cancer. The 
PoTRA analysis is based on topological ranks of genes in biological pathways, and 
PoTRA detects pathways involved in cancer by testing if the number of hub genes in 
pathways is altered between normal and cancer.  
To illustrate the method, PoTRA is applied to several TCGA hepatocellular carcinoma 
datasets. The results in our study are in agreement with prior knowledge of HCC from 
literature. We find that a high proportion of statistically significant pathways play 
important roles in cancer, indicating that the altered number of hub genes for these 
pathways might indeed be a reflection of the underlying biological causes that lead to 
cancer. Moreover, in the comparison between normal and each subtype of HCC, most 
importantly, the “Hepatitis B” pathway and several pathways associated with virus 
infection dramatically become significant pathways in hepatitis B-induced HCC, 
suggesting that PoTRA is capable of detecting pathways associated with disease 
subtypes. We also find several pathways associated with HCC generally and subtype 
specifically in hepatitis C-induced HCC and in alcohol-induced HCC. 
In our approach, the correlation method is used to construct gene co-expression 
networks for normal and cancer, respectively. A gene co-expression network is an 
undirected graph, where each node represents a gene, and each edge is established if 
there is a significant co-expression relationship between two genes (Stuart et al., 2003). 
Stuart JM, et al. (Stuart et al., 2003) found 22,163 co-expression relationships, each of 
which has been conserved across evolution, suggesting that the co-expressions between 
genes confers a selective advantage and thus these genes are functionally related. Gene 
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co-expression networks are biologically interesting since co-expressed genes might be 
controlled by members of the same pathway,  or the same transcriptional regulatory 
program or protein complex (Weirauch, 2011), and could be functionally related, 
suggesting that co-expression is common in the human genome. A gene co-expression 
network can be constructed by looking for pairs of genes with a similar expression 
pattern across samples, i.e., the transcript levels of two co-expressed genes rise and fall 
together across samples. Therefore, the correlation method used by PoTRA is capable to 
identify co-expressed gene pairs.  
 
2.5. Future Directions 
The hypothesis of our study is based on the fact that the loss of connectivity is a common 
topological trait of cancer networks (Anglani et al., 2014). It is not yet well understood if 
this trait is a characteristic of other complex diseases. Thus, we need to be cautious about 
the applicability of this method to other diseases. However, this trait could be applicable 
to other complex diseases. Thus, although PoTRA is motivated by work on cancer, it 
could apply to other complex diseases as well. This area needs to be further investigated. 
In this study, we apply PoTRA to pre-defined biological pathways, from the well-curated 
KEGG pathway database. However, the PoTRA method can also be applied to any set of 
genes of interest, such as functional gene subnetworks. This could be an interesting area 
to further explore.  
In addition to hub genes, bottleneck genes which have a high betweenness centrality 
(i.e., network nodes that have many “shortest paths” going through them, analogous to 
major bridges and tunnels on a highway map) are also fairly important for a biological 
network. Bottleneck gene are key connectors in gene network, bottlenecks are shown to 
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tend to be essential in gene network. Therefore, bottlenecks might be a good direction to 
further investigate.  
We can further validate the PoTRA method using simulated data. We might simulate a 
network (i.e., biological pathways) composed of 100 nodes (i.e., genes) using Barabasi-
Albert model (Albert & Barabási, 2002).  Also, we simulate an Erdos-Renyi random 
network (Erdős, 1959) composed of 100 nodes using an Erdos-Renyi random graph 
generator embedded in the R package “igraph” (Csárdi & Nepusz, 2006). The former 
network is a scale-free network, while the latter network is a random graph. Hence, the 
expected result is that those two networks are significantly different. Then PoTRA is 
applied to test if those two networks are different. 
For the PageRank algorithm, we use the default value of damping factor 0.85 in this 
study. However, the damping factor is not necessarily a fixed value in different cases. 
Hence, we might further use simulation to decide the best value of damping factor in 
different cases. This is a very interesting and valuable direction to explore. 
For those significant pathways that we identify, we might further hypothesize that there 
are some common genes in those significant pathways. These common genes could be 
driver genes to drive tumorigenesis. We might further find those common genes and 
investigate the biology behind some of results. 
 
2.6.  Conclusion 
In summary, PoTRA provides a new method for detecting cancer-associated pathways. 
PoTRA may be used to augment existing methods and provide a richer, more systematic 
understanding of cancer mechanisms. 
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2.7. Availability 
R software to carry out the PoTRA computation is available via 
http://www.dinulab.org/tools. 
 
2.8.  Supplementary Materials 
 
Gene 
Symbol PR_normal PR_cancer 
 
Gene 
Symbol PR_normal PR_cancer 
1 AKT3 0.003093905 0.00300372 156 MAP2K2 0.004305054 0.001979433 
2 CDK2 0.003040914 0.003949561 157 BAD 0.002098977 0.001537706 
3 CDK4 0.003391899 0.003442728 158 PTCH1 0.004896564 0.005416168 
4 CDK6 0.002710498 0.002632461 159 PTEN 0.003402329 0.004924039 
5 CDKN1A 0.003458217 0.001332768 160 PTK2 0.002923717 0.004069311 
6 CDKN1B 0.003636721 0.004189972 161 BAX 0.002922207 0.002322378 
7 CDKN2A 0.003618423 0.00271539 162 RAC1 0.002793632 0.004790566 
8 CDKN2B 0.004020755 0.007139137 163 RAC2 0.003750833 0.003195001 
9 LAMC3 0.003079645 0.002038664 164 RAC3 0.00343216 0.002457697 
10 TFG 0.003411381 0.003289014 165 RAF1 0.003089542 0.005300568 
11 CEBPA 0.002461461 0.003044095 166 RALA 0.002535952 0.005790368 
12 RALBP1 0.002763423 0.005092257 167 RALB 0.003030614 0.006514099 
13 RASSF1 0.002415298 0.003832637 168 RALGDS 0.002249478 0.00546576 
14 FZD10 0.005169905 0.001816191 169 RARA 0.005698338 0.004808868 
15 EGLN2 0.00353983 0.001187428 170 RARB 0.002455165 0.002768134 
16 EGLN3 0.003632638 0.002688535 171 RB1 0.002302646 0.005971465 
17 CHUK 0.003863949 0.004152228 172 CCND1 0.004082443 0.001725468 
18 CKS1B 0.004536644 0.002561939 173 BCL2 0.002264799 0.003741892 
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19 CKS2 0.00403055 0.00214326 174 RELA 0.00362278 0.003817114 
20 COL4A1 0.002642866 0.00282523 175 RET 0.001689008 0.000489237 
21 COL4A2 0.003103248 0.002153239 176 BCR 0.004432436 0.004640876 
22 COL4A3 0.003271212 0.001209817 177 RXRA 0.002619723 0.001323734 
23 COL4A4 0.002970752 0.003097248 178 RXRB 0.002878814 0.001746663 
24 COL4A5 0.006294353 0.001287653 179 BID 0.003641528 0.002462616 
25 COL4A6 0.001253758 0.000767639 180 SHH 0.004395602 0.004216858 
26 CRK 0.003741232 0.005513751 181 SKP2 0.003184264 0.002789141 
27 CRKL 0.00325282 0.004265987 182 SMO 0.002328005 0.00409342 
28 CTBP1 0.003456445 0.006251871 183 SOS1 0.003116838 0.003698003 
29 CTBP2 0.002354344 0.003178328 184 SOS2 0.003323926 0.005023092 
30 CTNNB1 0.002542315 0.003788528 185 SPI1 0.00434689 0.003165557 
31 DAPK1 0.003198525 0.005002724 186 BRAF 0.003482398 0.004239558 
32 DAPK3 0.004720648 0.004015498 187 STAT1 0.003735686 0.003035884 
33 DCC 0.001960459 0.001561484 188 STAT3 0.004346367 0.00316925 
34 DVL1 0.004021144 0.003689196 189 STAT5A 0.003173093 0.005400298 
35 DVL2 0.002631472 0.003972589 190 STAT5B 0.003293719 0.003781533 
36 DVL3 0.002227315 0.003796052 191 TCEB1 0.004751576 0.003317497 
37 EGF 0.00151036 0.002656015 192 TCEB2 0.001395063 0.003835255 
38 EGFR 0.003054758 0.005109083 193 TCF7 0.002361603 0.003532294 
39 EPAS1 0.003394586 0.004924966 194 TCF7L2 0.003775016 0.003724009 
40 ERBB2 0.004808457 0.001814885 195 TGFA 0.003914048 0.003407188 
41 AKT1 0.004401951 0.001514189 196 TGFB1 0.003614268 0.003182874 
42 AKT2 0.003416283 0.004092489 197 TGFB2 0.005255924 0.004529128 
43 ETS1 0.002538532 0.002663598 198 TGFB3 0.003103419 0.003000592 
44 MECOM 0.003437083 0.004944226 199 TGFBR1 0.00225014 0.003598152 
45 FGF1 0.003430158 0.001526164 200 TGFBR2 0.003613977 0.006812136 
46 FGF2 0.004045796 0.001289223 201 TP53 0.00252106 0.002459 
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47 FGF3 0.000491965 0.001395881 202 TPM3 0.002578494 0.004063351 
48 FGF4 0.000491965 0.001067975 203 TPR 0.002005053 0.003321939 
49 FGF5 0.002047965 0.001584524 204 HSP90B1 0.004129877 0.003999821 
50 FGF6 0.000491965 0.000489237 205 VHL 0.003158384 0.004027472 
51 FGF7 0.002577353 0.003851117 206 WNT1 0.003694857 0.00230586 
52 FGF8 0.000606536 0.001337488 207 WNT2 0.003875735 0.001715735 
53 FGF9 0.004940821 0.005184195 208 WNT3 0.004378124 0.002437254 
54 FGF10 0.002788004 0.002202358 209 WNT5A 0.003303738 0.002342169 
55 FGF11 0.003096608 0.004479963 210 WNT6 0.001516543 0.001345974 
56 FGF12 0.002897905 0.001349453 211 WNT7A 0.001472326 0.001254448 
57 FGF13 0.004025308 0.001043084 212 WNT7B 0.002526824 0.00251065 
58 FGF14 0.000491965 0.001825604 213 WNT8A 0.000861505 0.000595714 
59 FGFR1 0.003588912 0.00272812 214 WNT8B 0.000732661 0.000732088 
60 FGFR3 0.004824156 0.002028192 215 WNT10B 0.003746589 0.001971191 
61 FGFR2 0.002679216 0.002991078 216 WNT11 0.001458332 0.001480431 
62 LAMB4 0.003877415 0.001990161 217 WNT2B 0.004452958 0.002412174 
63 FLT3 0.0045477 0.00406583 218 WNT9A 0.004818818 0.002510426 
64 FLT3LG 0.004221203 0.002718439 219 WNT9B 0.000764811 0.00141332 
65 FN1 0.002612425 0.004331963 220 ZBTB16 0.001507095 0.00151374 
66 FOS 0.002060237 0.002313126 221 PAX8 0.004644468 0.001018703 
67 PIK3R5 0.003821391 0.003815514 222 FZD5 0.00309711 0.002893059 
68 DAPK2 0.003393029 0.000754584 223 FZD3 0.00419619 0.002834875 
69 CBLC 0.00419537 0.001124637 224 CCDC6 0.003320029 0.00622032 
70 ABL1 0.002828823 0.0054705 225 NCOA4 0.002797625 0.004216662 
71 FZD2 0.002945035 0.003247979 226 WNT10A 0.004112892 0.003183438 
72 APPL1 0.003033474 0.004534701 227 FGF23 0.001459143 0.001574117 
73 FGF20 0.001614757 0.001404174 228 WNT5B 0.002563388 0.000961552 
74 FGF21 0.003062587 0.003391477 229 FZD1 0.002984098 0.003891502 
32 
 
75 FGF22 0.001146482 0.000975682 230 FZD4 0.003876819 0.002179775 
76 STK36 0.002642641 0.003945146 231 FZD6 0.003020781 0.004240562 
77 GLI1 0.003813176 0.002437481 232 FZD7 0.003278225 0.002572302 
78 GLI2 0.003033217 0.002735696 233 FZD8 0.004655819 0.00337092 
79 GLI3 0.002741522 0.002361796 234 FZD9 0.002771345 0.000786142 
80 LAMA1 0.005807073 0.001932564 235 TCF7L1 0.004644479 0.00349625 
81 GRB2 0.002216502 0.005585664 236 RASSF5 0.002955222 0.002820201 
82 GSK3B 0.002274372 0.00450013 237 CASP3 0.003064809 0.003100381 
83 HDAC1 0.002668862 0.004121253 238 CASP8 0.003093951 0.005910365 
84 HGF 0.003404592 0.002564872 239 CASP9 0.005074869 0.001516088 
85 HIF1A 0.003504699 0.005674787 240 CUL2 0.002964537 0.004349557 
86 HRAS 0.005395857 0.002094702 241 PIK3R3 0.003215646 0.006488887 
87 HSP90AA1 0.00370572 0.005317323 242 IKBKG 0.004975669 0.001201659 
88 HSP90AB1 0.0026485 0.003443134 243 RUNX1 0.004289037 0.004484772 
89 IGF1 0.00189462 0.001526586 244 RUNX1T1 0.003926335 0.001790019 
90 IGF1R 0.003374734 0.000692951 245 CBL 0.003308481 0.005999363 
91 FAS 0.002947965 0.002274438 246 CBLB 0.00236811 0.008074871 
92 IKBKB 0.002621242 0.005865599 247 FADD 0.004632577 0.004130511 
93 FASLG 0.003489903 0.003679946 248 FGF18 0.005343563 0.002291649 
94 ITGA6 0.002667856 0.003401315 249 FGF17 0.001685853 0.001240543 
95 AR 0.001843612 0.003851707 250 FGF16 0.000491965 0.001716323 
96 ITGA2 0.004255997 0.003790406 251 WNT3A 0.000670711 0.001163439 
97 ITGA2B 0.001779879 0.001293375 252 CCNE1 0.003777607 0.004063126 
98 ITGA3 0.004571272 0.002333706 253 PIAS2 0.003294104 0.003706514 
99 ITGAV 0.002577937 0.004511556 254 CCNE2 0.003829759 0.003024707 
100 ITGB1 0.002722552 0.005512016 255 FGF19 0.002041663 0.001547215 
101 ARAF 0.003770923 0.001648577 256 RBX1 0.003486231 0.00197113 
102 JAK1 0.00215008 0.006380458 257 FOXO1 0.001463804 0.001110548 
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103 JUN 0.004604203 0.001826207 258 MTOR 0.002418695 0.002870981 
104 JUP 0.004523251 0.003669617 259 CSF3R 0.004223332 0.003860835 
105 KIT 0.004796668 0.000915436 260 E2F1 0.003990438 0.003854594 
106 KRAS 0.003798401 0.005525741 261 E2F2 0.004058837 0.0054384 
107 RHOA 0.002574591 0.004360737 262 E2F3 0.004336313 0.005194975 
108 LAMA2 0.003538299 0.001851764 263 IL6 0.002959906 0.003059989 
109 LAMA3 0.004591861 0.000850307 264 CDC42 0.002459057 0.00483741 
110 LAMA4 0.002821443 0.003242991 265 STK4 0.002657375 0.005353271 
111 LAMA5 0.005952102 0.005213777 266 HDAC2 0.003097869 0.004292515 
112 LAMB1 0.002557073 0.004371683 267 CREBBP 0.002935804 0.003175403 
113 LAMB2 0.003725664 0.003748125 268 EP300 0.00263447 0.005360202 
114 LAMB3 0.004672454 0.000787888 269 VEGFD 0.001163632 0.000784671 
115 LAMC1 0.002311235 0.00289013 270 ARNT 0.002580086 0.004391662 
116 LAMC2 0.002608833 0.00198952 271 PGF 0.004505714 0.002935848 
117 SMAD2 0.002249808 0.004860795 272 SLC2A1 0.005452944 0.003071782 
118 SMAD3 0.002707199 0.004199273 273 VEGFA 0.0039616 0.004470881 
119 MAX 0.002868878 0.005076557 274 VEGFB 0.002820038 0.003698483 
120 MDM2 0.003558278 0.00347452 275 VEGFC 0.003742468 0.003304904 
121 MET 0.003552921 0.004114956 276 ARNT2 0.003321398 0.002836696 
122 KITLG 0.004774841 0.002835445 277 CXCL8 0.004633571 0.003557386 
123 MYC 0.004252456 0.002505314 278 MMP1 0.002590167 0.002904235 
124 NFKB1 0.004045736 0.00458389 279 MMP2 0.003286815 0.002153179 
125 NFKB2 0.003607195 0.004612478 280 MMP9 0.002602466 0.001893486 
126 NFKBIA 0.004361484 0.001949027 281 HHIP 0.003682677 0.002921235 
127 NKX3-1 0.004297668 0.002708324 282 BMP2 0.003422092 0.002578134 
128 NRAS 0.002567488 0.00432757 283 BMP4 0.003690261 0.002081375 
129 NTRK1 0.004454522 0.001981356 284 PTCH2 0.002954986 0.003976521 
130 LEF1 0.003495041 0.002350695 285 KLK3 0.000509865 0.000737893 
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131 WNT16 0.001098482 0.001409997 286 PPARD 0.00302206 0.005249179 
132 PDGFA 0.003389003 0.002862777 287 MAPK8 0.003270075 0.003491051 
133 PDGFB 0.004505859 0.004401392 288 MAPK9 0.002383262 0.003928425 
134 PDGFRA 0.002673138 0.003186629 289 MAPK10 0.002947271 0.002123566 
135 PDGFRB 0.00297555 0.003415683 290 SMAD4 0.003325315 0.004625337 
136 SUFU 0.002317984 0.00358168 291 BIRC8 0.000491965 0.000489237 
137 PIK3CA 0.003414598 0.004320752 292 BIRC2 0.002887534 0.003677406 
138 PIK3CB 0.002565891 0.004433264 293 BIRC3 0.004145515 0.002910634 
139 PIK3CD 0.00347652 0.002307271 294 XIAP 0.003063954 0.005127472 
140 PIK3CG 0.003017476 0.003016939 295 NOS2 0.0020443 0.000828748 
141 PIK3R1 0.00334452 0.003301249 296 PTGS2 0.005697117 0.002183857 
142 PIK3R2 0.004332678 0.002937172 297 BCL2L1 0.004366514 0.003791546 
143 PLCG1 0.002311099 0.00631182 298 TRAF1 0.003487191 0.003371306 
144 PLCG2 0.003709433 0.002335372 299 TRAF2 0.003406522 0.003587955 
145 PML 0.003385369 0.00523318 300 TRAF3 0.002531222 0.004840198 
146 CYCS 0.004858868 0.003588693 301 TRAF5 0.003799039 0.004325504 
147 WNT4 0.004326655 0.001893445 302 TRAF6 0.003200779 0.006150486 
148 EGLN1 0.004057612 0.004247422 303 BIRC7 0.003638758 0.001685454 
149 PPARG 0.004018764 0.003434064 304 TRAF4 0.003163841 0.002732923 
150 PRKCA 0.003893901 0.00340499 305 BIRC5 0.004552145 0.002196816 
151 PRKCB 0.00300293 0.002937265 306 CCNA1 0.003085372 0.001829558 
152 PRKCG 0.0019237 0.000489237 307 RXRG 0.00263539 0.002051522 
153 MAPK1 0.002567474 0.003750868 308 PLD1 0.003675508 0.002758496 
154 MAPK3 0.002835883 0.00451274 309 CSF1R 0.004301397 0.003872604 
155 MAP2K1 0.001598758 0.005993616 310 CSF2RA 0.004469274 0.005738579 
Table 2.7. The PageRank scores of genes in “Pathways in cancer” for normal and 
cancer. We consolidate the information from Section 1.1 – Section 1.2 into one table 
with four columns, namely: (1) Gene index (1-310) (2) Gene symbol (3) The PageRank 
score of each gene in this pathway for normal (4) The PageRank score of each gene in 
this pathway for cancer. 
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Chapter 3: miR2Pathway: A Novel Analytical Method to Discover MicroRNA-
mediated Dysregulated Pathways Involved in Disease 
 
3.1. Introduction 
MicroRNAs (miRNAs) are short non-coding RNAs of about 22 nucleotides in length, 
involved in the post-transcriptional regulation of gene expression. MiRNAs induce the 
degradation of mRNA or translational repression of mRNA depending on the degree of 
homology to specific sequences, typically in the untranslated regions (UTRs) of their 
targets (Pasquinelli, 2012). MiRNAs are able to impact the expression of one or many 
genes at a time. It is believed that more than 60% of human genes are regulated by 
miRNAs (Friedman et al., 2009). Hence, miRNAs can be important regulators of 
biological processes. For example, a single miRNA can control a complex biological 
pathway by simultaneously targeting multiple mRNAs of this specific biological pathway, 
and these targeted mRNAs might be members of a cascade functioning towards a 
functional endpoint in the same biological pathways or in the crosstalk between 
biological pathways (Lima et al., 2011). Over the past years, the role of miRNAs as key 
regulators that control a wide variety of fundamental biological processes involved in 
proliferation, apoptosis, cell growth, differentiation, invasiveness, motility, other 
oncogenic related processes, etc., has been demonstrated (Calin & Croce, 2006; Kefas et 
al., 2008; Saydam et al., 2009; Ponomarev et al., 2011; van Kouwenhove, Kedde & 
Agami, 2011; Lu et al., 2011; Glass & Singla, 2011; Fu et al., 2012; Fang et al., 2012). For 
example, Lu and colleagues show that miRNA-21 is able to down-regulate the activity of 
the IL-12/IFN-γ pathway in lung cancer (Lu et al., 2011, p.). Other research teams have 
found that miRNA-7 can simultaneously target multiple genes of the PI3-kinase/Akt 
pathway in hepatocellular carcinoma and glioblastoma (Kefas et al., 2008; Fang et al., 
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2012). MiRNA-200 functions as a multifunctional tumor suppressor in meningiomas 
through multiple and simultaneous influences on the E-cadherin and Wnt/β-catenin 
signaling pathways (Saydam et al., 2009). MiRNA-106a has been shown to directly 
inhibit ULK1 mRNA expression levels in acute myeloid leukemia (AML) cells, and also 
can target other members of the ULK1 complex, such FIP200 and mAtg13 (Fu et al., 
2012). The C/EBP-α-PU.1 pathway is found to be regulated by miRNA-124 (Ponomarev 
et al., 2011), and miRNA-1 has been suggested to inhibit Pten/Akt pathway (Glass & 
Singla, 2011). MiRNAs are often aberrantly expressed in tumor tissue even in early stages 
of tumor and other conditions (Negrini et al., 2007; Croce, 2009), which can make them 
valuable biomarker candidates, such as for Alzheimer’s disease (AD) (Leidinger et al., 
2013). Furthermore, several studies have demonstrated a potential value of miRNA-
based therapy in cancer (Takamizawa et al., 2004; Cimmino et al., 2005; Scott et al., 
2007; Kasinski & Slack, 2011). A good example is the utility of anti-miRNA-21 in breast 
cancer, resulting in suppression of tumor growth in vivo and cell growth in vitro (Si et al., 
2007). Therefore, miRNAs’ potential as disease biomarkers and therapeutic agents 
places this group of small non-coding RNAs at the cutting-edge position of biomedical 
interest. Therefore, an important question is raised based on the generality of the above 
phenomena: What degree of miRNA-mediated dysregulation of biological pathways is 
present in disease?  
Over the past decade, there has been a large volume of literature demonstrating that 
miRNAs dysregulate mRNA expression levels by their aberrant expression in diseases 
(Takamizawa et al., 2004; Cimmino et al., 2005; Scott et al., 2007; Si et al., 2007; Kefas 
et al., 2008; Saydam et al., 2009; Ponomarev et al., 2011; Lu et al., 2011; Glass & Singla, 
2011; Fang et al., 2012; Leidinger et al., 2013; Ding et al., 2015). That is to say, the 
targeted mRNAs’ expression might be aberrantly altered because they are incorrectly 
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regulated by aberrantly expressed miRNAs. Based on this, several tools have been 
developed to detect miRNA-pathway associations (Nam et al., 2009; Maragkakis et al., 
2011; Hsu et al., 2011a; Lu et al., 2012; Ben-Hamo & Efroni, 2015; Godard & van Eyll, 
2015; Preusse, Theis & Mueller, 2016; Backes et al., 2016; Han et al., 2016; Backes et al., 
2017). These tools typically propose enrichment-based methods to study associations 
between miRNAs and pathways. These enrichment-based methods, however, have two 
common limitations. First, they study the association between miRNA and pathway 
based on enrichment analysis of targeted genes in a pathway. Hence, they ignore the 
topological importance of targeted genes in a pathway. For example, if a miRNA targets 
genes of topological importance in a pathway, such as hub genes, this miRNA might have 
higher association with the activity of this pathway than another miRNA that targets less 
topologically important genes. Second, these methods do not aim to identify changes in 
pathways between disease and non-disease. Instead, they focus on how miRNAs’ 
aberrant expression affect the targeted genes in a pathway, and do not assess how 
rewired miRNA-mRNA connections influence a pathway. 
It is well known that genes interact in complex networks that govern cellular processes. 
Researchers have discovered how rewired miRNA-mRNA connections influence 
biological processes in cancer. An important reason why the rewired miRNA-mRNA 
connections influence biological processes in cancer is that miRNA-mRNA connections 
tend to be dynamic or condition-specific, or differential between disease and non-
disease. For example, Volinia and colleagues (Volinia et al., 2010) have analyzed the 
genetic networks of miRNAs in cancer, and suggested that in normal tissues, miRNAs 
are connected in networks and different cell types have different network connections. In 
cancer, they suggest that it is likely that normal network connections become disrupted 
or rewired, which might contribute to disease. In addition, Chen-Ching Lin, et al. (Lin et 
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al., 2015) have identified a regulatory feedback loop between STAT1 and miRNA-155-5p 
that is consistently activated in cancer, and found that the rewired regulatory networks 
are highly associated with cancer. Sivan Elhanati, et al. (Elhanati et al., 2016) have found 
that miRNA-122 and SIRT6 negatively regulate each other’s expression, and the 
connection between them is manifested in two physiologically relevant ways in the liver. 
First, they negatively regulate a similar set of metabolic genes and fatty acid β-oxidation. 
Second, they found that the loss of a negative correlation between SIRT6 and miRNA-
122 expression is significantly associated with better prognosis in hepatocellular 
carcinoma patients. There are also analytical approaches for exosomal miRNA 
expression analysis (Aqil et al., 2014, 2015). Thus, there is an increasing number of 
relevant studies suggesting that rewired connections between miRNAs and genes are 
associated with diseases. However, these studies mainly focus on rewired connections 
between miRNAs and genes, but do not discuss how those rewired miRNA-mRNA 
connections are associated with dysregulation of biological pathways at the pathway-
level.  
A recent methodology developed by Kang et al  can analyze topological features of 
miRNA-target gene differential regulatory network (Kang et al., 2017). However, they 
use “degree” as the topological measurement in their study. “Degree” does not consider 
the topological weight of each gene in gene regulatory networks. Hence, we need to 
consider this in our study. Our analysis uses PageRank, an algorithm initially used by 
Google Search to rank websites in search engine results (Page et al., 1999). It is a way of 
measuring the importance of nodes in a network. More generally, PageRank has been 
applied to other networks, e.g., social networks (Pedroche et al., 2013; Wang et al., 
2013). To date, there have been several studies that also use PageRank to analyze miRNA 
(Noh et al., 2014; Xu et al., 2016; Wang & Cai, 2016). Xu, et al. (Xu et al., 2016) focuses 
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on miRNA-transcription factor (TF)-mRNA regulatory networks, and they use their 
method to identify the miRNA-TF-mRNA regulatory network for clustering samples with 
different cancer subtypes and achieve the goal of cancer subtype classification. Noh, et al. 
(Noh et al., 2014) focuses on identifying a set of miRNA-mRNA connections that are 
changed in Alzheimer’s disease. Wang, et al. (Wang & Cai, 2016) uses PageRank to rank 
miRNAs and mRNAs, separately, and to select the top ranked ones as biomarkers for 
ischemic stroke. Although these studies make use of PageRank, their focus is totally 
different from our approach. 
Here, we propose a new PageRank-based method, called miR2Pathway, to rank disease 
risk of rewired miRNA-mediated biological pathways and we apply it to study HCC. For 
example, in a hypothetical case 1, a miRNA regulates several hub genes in a pathway in 
normal tissue, while it loses the regulatory connections in tumor tissue; in case 2, this 
miRNA regulates the same number of non-hub genes in this pathway in normal tissue, 
while it loses the regulatory connections in tumor tissue. In this scenario, our hypothesis 
is that this miRNA has a larger differential influence on the activity of the pathway in 
case 1 than case 2. This is also related to the basic idea of PageRank (Page et al., 1999) 
that the topology of a node is high in a network if this node has connections to other 
nodes with high topology. Using a PageRank-based approach, miR2Pathway focuses on 
quantifying the differential effects of miRNAs on the activity of a biological pathway 
when miRNA-mRNA connections are altered from normal to HCC. miR2Pathway 
provides a new insight to explore HCC mechanism. Thus, miR2Pathway is a novel 
method that can identify miRNA-dysregulated pathways in cancer and has several 
characteristics which are different from previous methods (Nam et al., 2009; Maragkakis 
et al., 2011; Hsu et al., 2011a; Lu et al., 2012; Ben-Hamo & Efroni, 2015; Godard & 
van Eyll, 2015; Preusse, Theis & Mueller, 2016; Backes et al., 2016; Han et al., 2016; 
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Backes et al., 2017): (1) It can identify the relationship between a set of miRNAs and a set 
of pathways. (2) It focuses on identifying changes in miRNA-mediated pathways 
between control and case, while the other methods focus on finding pathways enriched 
in genes targeted by miRNAs. (3) It focuses on identifying the topological changes in 
miRNA-mediated pathways between control and case, while the other methods do not 
assess or use topological changes. These characteristics, particularly (2) and (3), make it 
difficult to compare miR2Pathway with other methods because miR2Pathway addresses 
a different question from the other methods.  
 
3.2. Materials and Methods 
An overview of the miR2Pathway method is illustrated in Figure 3.1. Briefly, gene and 
microRNA expression profiles are used to construct connections between each miRNA 
and genes of each pathway for control and case, respectively. Subsequently, we obtain 
the corresponding differential network between control and case for each miRNA-
Pathway pair. We can find the genes targeted by the miRNA in this differential network. 
Then, PageRank can be applied to measure the topological influence (PageRank scores) 
of the targeted genes in this differential network, which quantifies the topological 
influence of the genes that are differentially targeted by a miRNA on the activity of this 
pathway. Next, we can calculate the sum of PageRank scores of genes targeted by the 
miRNA in the differential network, which estimates the total differential influence of a 
miRNA on the activity of this pathway. Then, the same procedure is repeated for all 
miRNAs. We obtain a corresponding sum of PageRank scores for each miRNA. For a 
specific pathway, we then assess the total differential influence of all the miRNAs on this 
pathway through summing up all the sums corresponding to all the miRNAs. The total 
differential influence of all the miRNAs on this pathway reflects the degree of miRNA-
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mediated dysregulation of this pathway. We do this for all the pathways. Finally, we rank 
all pathways by the degree of miRNA-mediated dysregulation scores. 
 
 
Figure 3.1. An overview of miR2Pathway. 
 
3.2.1. Data  
For illustration, we use RNA-seq data of matched miRNA and mRNA from The Cancer 
Genome Atlas (TCGA) hepatocellular carcinoma (HCC) study 
(https://cancergenome.nih.gov/). The dataset contains expression levels for 1,046 
miRNAs and 20,531 mRNAs. We apply miR2Pathway to analyzing four datasets, 
containing 50 HCC samples and 50 tumor-adjacent normal samples, 34 hepatitis C-
induced HCC samples and 34 tumor-adjacent normal samples, 22 hepatitis B-induced 
HCC samples and 22 tumor-adjacent normal samples and 50 alcohol-induced HCC 
samples and 50 tumor-adjacent normal samples. Tumor-adjacent normal samples in 
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following sections will be referred to as normal samples. Pathway information from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa & Goto, 2000) 
is used. 
 
3.2.2.  Construct connections between each miRNA and genes of each 
pathway 
3.2.2.1. Predicted and validated MiRNA targets 
Five miRNA target site prediction programs (DIANA (Maragkakis et al., 2011), 
Targetscan (Friedman et al., 2009), PicTar (Lall et al., 2006), Miranda (Enright et al., 
2003) and miRDB (Wong & Wang, 2015)) are employed to obtain putative miRNA target 
genes for all 1,046 miRNAs. These five programs are included in the “miRNAtap” R 
package. Therefore, in practice, we implement the miRNA target site prediction by using 
miRNAtap. We select potential target genes when they are identified by at least two of 
five programs. Three validated miRNA target site databases (miRecords (Xiao et al., 
2009), miRTarBase (Hsu et al., 2011b) and TarBase (Vergoulis et al., 2012)) are used to 
obtain validated miRNA target genes for all 1,046 miRNAs. These three databases are 
included in the “multiMiR” R package and database. We select validated target genes 
when they are present in at least one of these three databases.  
 
3.2.2.2. Statistical analysis of miRNAs and target genes 
As we know, miRNA expression is negatively correlated with mRNA expression. To 
statistically identify the miRNA-mRNA connections in the regulatory network, we define 
a statistical connection between a miRNA and its target genes if the Pearson’s correlation 
between them is less than a series of cutoffs (-0.4, -0.3, -0.2, -0.1) and the corresponding 
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p-value of the Pearson’s correlation is < 0.05. We implement it through a built-in 
function called “cor.test()” in the statistical software package R (https://www.r-
project.org/). This is done separately for case and control samples. 
 
3.2.2.3. Identification of connections between miRNAs and mRNAs 
Based on the results above, we use the intersection of the sets from Step 2.1 and Step 
2.2 as the identified miRNA-mRNA connections, which are used for the following 
analysis. 
Note, for Steps 2.1-2.3, we only determine the connections between miRNAs and target 
genes. For the construction of pathways, we directly obtain gene-gene connections 
within pathways from KEGG (Kanehisa & Goto, 2000). We pre-define the topology of 
pathways from KEGG and observe alterations of miRNA-mRNA connections in our 
study, thereby we can better quantify the degree by which miRNAs differentially 
influence the activity of each pathway between control and case. 
 
3.2.2.4. Construct a miRNA-Pathway regulatory network 
Next, we construct the miRNA-Pathway networks, i.e., construct each network consisting 
of a single miRNA and a single pathway. First, we obtain the gene list of a specified 
pathway from KEGG. Second, for each miRNA, we select the identified miRNA-mRNA 
connections specific for this pathway. Finally, we merge these identified miRNA-mRNA 
connections into the topology of this pathway derived from KEGG. The result is a 
miRNA-Pathway network. This is done separately for case and control samples. 
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3.2.3. Differential networks for miRNA-Pathway pairs  
Based on the constructed miRNA-Pathway regulatory networks for control and case, 
separately, we can easily find the corresponding differential networks between control 
and case, see Figure 3.2. 
a.    b.     c.  
Figure 3.2. Construction of differential networks. (a) is a miRNA-Pathway 
regulatory network for control. (b) is the miRNA-Pathway regulatory network for case. 
(c) is the differential miRNA-Pathway regulatory network between control and case. A 
differential connection is constructed if it appears in either one of (a) and (b) while it 
does not appear in the other one. The green nodes represent genes and the blue node 
represents a miRNA.  
 
Notably, all the networks in our study are based on correlation, thus, all of them are 
undirected graphs.  
 
3.2.4. Measure the differential influence of miRNAs on the activity of 
pathways 
3.2.4.1. Measure the differential influence of a single miRNA on a 
single pathway 
To summarize, up to this point the algorithm finds the differential miRNA-Pathway 
network, which provides information about the differential influence of a miRNA on the 
activity of a pathway between control and case. The null hypothesis is that there is no 
difference in the miRNA-Pathway network between control and case, indicating that the 
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differential miRNA-Pathway network has an isolated miRNA. In other words, the single 
miRNA has no differential influence on the activity of this pathway. Conversely, if this 
miRNA has many differential connections in the miRNA-Pathway network between 
control and case, and, even more importantly, has differential connections with hub 
genes in this pathway, it suggests that this miRNA has a large differential influence on 
the activity of this pathway between control and case samples.  
In this step, we measure the differential influence of a miRNA on the activity of this 
pathway between control and case using PageRank (Page et al., 1999), see Eq. (1). 
 𝑆𝑖,𝑗 =  𝑃𝑅(𝑇𝐺)𝑖,𝑗,1 +  𝑃𝑅(𝑇𝐺)𝑖,𝑗,2 + ⋯ +  𝑃𝑅(𝑇𝐺)𝑖,𝑗,𝑘                                     (1) 
In Eq.  (1), Si,j is the sum of PageRank (PR) score of targeted genes (TG) of the miRNA i 
for the pathway j in the differential miRNA-Pathway network. The letter i denotes the 
index of a miRNA, the letter j denotes the index of a pathway and letter k denotes the 
number of targeted genes of the miRNA i in the corresponding differential miRNA-
Pathway network. Si,j quantifies the differential influence of the miRNA i on the activity 
of the pathway j between control and case. Since PageRank considers the sum of 
PageRank scores of all the nodes in a network equal to 1, Si,j ranges from 0 to 1. When Si,j 
= 0, it indicates that the miRNA i does not differentially regulate genes of the pathway j 
between control and case. When Si,j = 1, it indicates that the miRNA i differentially 
regulates all genes of the pathway j between control and case.  
 
3.2.4.2. Measure the total differential influence of a set of miRNAs on a 
single pathway 
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For this same pathway, we repeat the same procedure from Step 4.1 for all miRNAs of 
interest.  We obtain different Si,j (i=1,2,…,M, where M is the number of miRNAs and j is 
the index of the pathway) for each miRNA. Then, we assess the total differential 
influence of all the miRNAs on this pathway through summing up all the Si,j scores, see 
Eq. (2).  
 𝑇𝑗 =  𝑆1,𝑗 +  𝑆2,𝑗 + ⋯ +  𝑆𝑀,𝑗                                                                                (2) 
In Eq. (2), Tj is the sum of all the S scores corresponding to all the miRNAs for pathway j. 
The letter M represents the number of miRNAs, and the letter j represents the index of a 
pathway. The T score quantifies the total differential influence of all the miRNAs on the 
activity of a single pathway between control and case. If Tj is larger, it suggests that 
miRNAs differentially regulate a larger number of genes and/or differentially regulate 
hub genes in pathway j between control and case. Hence, the T score can reflect the 
degree of miRNAs dysregulating a single pathway. 
 
3.2.5. Rank pathways based on disease risk of miRNA-mediated 
dysregulation of biological pathways 
We repeat Step 4 to obtain a corresponding T score for each pathway. Finally, we rank all 
pathways by their T scores, which are measures of the degree of miRNA-mediated 
dysregulation.  
 
3.2.6. Software tools 
All the analysis is conducted using the R programming language. We use the following R 
Biocoductor packages: parallel for parallel computing, graphite for pathway databases, 
47 
 
igraph for PageRank function, graph for visualization, miRNAtap for miRNA target site 
prediction.   
  
3.3. Results 
First, we apply miR2Pathway to analyze HCC samples and normal samples. We use as 
example the interaction between miRNA-122 and the “MicroRNAs in cancer” pathway. 
MiRNA-122 is reported to be specific for liver cancer in several studies (Coulouarn et al., 
2009; Li et al., 2012; Tsai et al., 2012; Bandiera et al., 2015), and “MicroRNAs in cancer” 
is a miRNA-related pathway. We are interested in seeing how miRNA-122 differentially 
influences the activity of this pathway. Figure 3.3 shows the topological structure of the 
pathway “MicroRNAs in cancer”. 
                                                           
Figure 3.3. The pathway “MicroRNAs in cancer”. We directly obtain the 
topological structure of this pathway from the KEGG database. There are 262 genes in 
this pathway, and there are 518 connections between genes in this pathway. The number 
inside each node is the corresponding gene ID. For gene names, see Table 3.3. 
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3.3.1. Construct connections between miRNA-122 and genes of the 
pathway “MicroRNAs in cancer” for normal and HCC 
Based on the topological structure of this pathway, we need to know which gene(s) is/are 
targeted by miRNA-122 in this pathway for normal and cancer, separately. After we 
complete Step 2.3, we identify connections between miRNA-122 and genes of this 
pathway “MicroRNAs in cancer”. In Figure 3.4, as an example, we only show the 
identified connections between miRNA-122 and genes based on predicted targets using a 
correlation cutoff of -0.4.  
 
a.        b.     
Figure 3.4. The interaction between miRNA-122 and the “MicroRNAs in 
Cancer” pathway for normal (a) and cancer (b), separately.  
 
Figure 3.4 shows that miRNA-122 targets one gene (geneID is 6541 and gene symbol is 
CAT-1 or SLC7A1) in normal, while it does not target this gene in HCC. Very 
interestingly, several studies show that CAT-1/SLC7A1 is a well-known target gene of 
miRNA-122 (Chang et al., 2004; Yang & Kaye, 2009; Gatfield et al., 2009; Cirera et al., 
2010; Li et al., 2012). CAT-1/SLC7A1 is an important protein for liver tissue. It is a 
carrier protein required in the regenerating liver for the transport of cationic amino acids 
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and polyamines in the late G1 phase, a process that is essential for liver cells to enter 
mitosis, and CAT-1/SLC7A1 is involved in amino acid metabolism (Chang et al., 2004). 
Besides, several studies show that miRNA-122’s loss of function has been observed in 
liver cancer (Coulouarn et al., 2009; Hsu et al., 2012; Tsai et al., 2012; Thakral & 
Ghoshal, 2015). Thus, this result suggests that miRNA-122’s loss of function probably 
leads to loss of a connection between miRNA-122 and CAT-1/SLC7A1 in the HCC 
samples. Therefore, this result is well consistent with the evidence from prior literature. 
 
3.3.2.  A differential network between normal and cancer 
Based on the result illustrated in Figure 3.4, we can easily obtain the differential 
network between normal and cancer, whose topological structure is the same as Figure 
3.4(a).  
 
3.3.3.  Measure the differential influence of miRNAs on activities of this 
specified pathway between normal and cancer 
Based on the differential network above, we assess the topological influence of genes 
dysregulated by miRNA-122 in this pathway through calculating PageRank scores of 
targeted genes in the differential network. Namely, the PageRank score of the gene CAT-
1/SLC7A1 in the pathway is 0.002647686, which is also shown in Table 3.3. In Table 
3.3, we also compute and include eigenvector centrality, which is another topological 
measure of the “MicroRNAs in cancer” pathway, which was discussed previously in 
literature (Mallik & Maulik, 2015). However, we only discuss and use PageRank scores 
for genes of each pathway in our study. 
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In this way, we measure the differential influence of all other miRNAs on the activity of 
the pathway “MicroRNAs in cancer”, then we sum up the differential influence of all the 
miRNAs as a total one (i.e., T score). This total score, T = 0.139, is the degree of miRNA-
mediated dysregulation of the pathway of “MicroRNAs in cancer”.  
 
3.3.4. Rank miRNA-mediated dysregulation of all pathways 
Similarly, we obtain a corresponding total score T for each pathway. Then, we rank 
pathways using the T scores and show the top 50 pathways of miRNA-mediated 
dysregulation in Table 3.1, using a Pearson correlation cutoff value of -0.4 . As 
mentioned in Materials and Methods, we also tested several other correlation cutoffs:  
-0.3, -0.2, -0.1. The results are very similar to those from Table 3.1 and are included in 
Table 3.6, Table 3.7 and Table 3.8, respectively. 
 
 
Gene Count(L) T score 
1 FoxO signaling pathway 126 0.652 
2 Circadian rhythm 31 0.418 
3 Hedgehog signaling pathway 47 0.375 
4 Notch signaling pathway 48 0.354 
5 Hippo signaling pathway -multiple species 29 0.333 
6 Dorso-ventral axis formation 13 0.315 
7 Cytosolic DNA-sensing pathway 21 0.265 
8 Thyroid cancer 28 0.257 
9 Shigellosis 51 0.253 
10 Inflammatory bowel disease (IBD) 48 0.242 
11 RNA degradation 18 0.217 
12 Toll-like receptor signaling pathway 104 0.207 
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13 
AGE-RAGE signaling pathway in diabetic 
complications 91 
0.203 
14 Wnt signaling pathway 137 0.177 
15 MAPK signaling pathway 252 0.175 
16 Cocaine addiction 42 0.168 
17 mTOR signaling pathway 144 0.159 
18 Oocyte meiosis 120 0.155 
19 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 10 
0.154 
20 
Epithelial cell signaling in Helicobacter pylori 
infection 37 
0.153 
21 Insulin resistance 94 0.151 
22 Pancreatic cancer 65 0.142 
23 Steroid biosynthesis 20 0.142 
24 MicroRNAs in cancer 262 0.139 
25 HTLV-I infection 194 0.137 
26 Progesterone-mediated oocyte maturation 89 0.129 
27 Adipocytokine signaling pathway 63 0.128 
28 Rap1 signaling pathway 208 0.127 
29 Acute myeloid leukemia 57 0.115 
30 Hepatitis C 97 0.114 
31 Ether lipid metabolism 44 0.110 
32 Hepatitis B 134 0.107 
33 Leishmaniasis 50 0.101 
34 Glyoxylate and dicarboxylate metabolism 26 0.097 
35 Herpes simplex infection 104 0.095 
36 Pantothenate and CoA biosynthesis 16 0.094 
37 Huntington's disease 27 0.092 
38 Vascular smooth muscle contraction 114 0.091 
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39 Antigen processing and presentation 62 0.091 
40 Breast cancer 143 0.088 
41 Calcium signaling pathway 179 0.085 
42 Long-term potentiation 67 0.085 
43 Chagas disease (American trypanosomiasis) 89 0.084 
44 Estrogen signaling pathway 89 0.082 
45 RIG-I-like receptor signaling pathway 48 0.082 
46 p53 signaling pathway 68 0.080 
47 Osteoclast differentiation 123 0.079 
48 Toxoplasmosis 93 0.077 
49 Gap junction 88 0.076 
50 Vasopressin-regulated water reabsorption 22 0.075 
Table 3.1. Top 50 pathways ranked by T score comparing normal with HCC samples 
based on the Pearson’s correlation cutoff (-0.4).  
Interestingly, we find in Table 3.1 a large number of pathways associated with cancer in 
general and liver cancer specifically. First, the “microRNAs in cancer” pathway is listed 
in the top 50 pathways, which suggests that miRNA-mediated dysregulation is able to 
contribute to cancer (Garzon, Calin & Croce, 2009; Kwak, Iwasaki & Tomari, 2010; 
Jansson & Lund, 2012). FoxO signaling pathway is top-ranked and known to be involved 
in the regulation of the cell cycle, apoptosis, and metabolism. The second ranked 
pathway, circadian rhythm, is well known to be implicated in cancer (Fu & Kettner, 2013; 
Blakeman et al., 2016). Hedgehog signaling pathway is a major regulator of many 
fundamental processes in vertebrate embryonic development including stem cell 
maintenance, cell differentiation, tissue polarity and cell proliferation (Evangelista, Tian 
& de Sauvage, 2006; Rubin & de Sauvage, 2006; Gupta, Takebe & LoRusso, 2010; 
Gonnissen, Isebaert & Haustermans, 2015). Notch signaling pathway is one of the most 
commonly activated signaling pathways in cancer, and plays a key role in cell 
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proliferation, differentiation and survival (Capaccione & Pine, 2013; Guo et al., 2014; 
Yuan et al., 2015). Hippo signaling pathway is reported to be able to control organ size 
through regulating cell proliferation and apoptosis (Saucedo & Edgar, 2007; Pan, 2010). 
Wnt signaling pathway is a well-known pathway specific for liver cancer.  The 
deregulation of the Wnt signaling pathway is early event in hepatocarcinogenesis and 
Wnt signaling pathway plays a critical role in liver development, regeneration, and 
promoting tumor formation in this organ (Takigawa & Brown, 2008; Waisberg & Saba, 
2015; Wang et al., 2017). MAPK signaling pathway is involved in the regulation of 
survival, cellular growth, gene expression (Knight & Irving, 2014). Deregulation of 
MAPK signaling pathway can lead to uncontrolled or increased cell proliferation and 
resistance to apoptosis (Santarpia, Lippman & El-Naggar, 2012; Burotto et al., 2014). 
mTOR signaling pathway is a well-known cancer-associated pathway. Alterations of 
mTOR signaling pathway have significant effects on cancer progression. The major 
components of mTOR signaling pathway are critical effectors in cell signaling pathways 
commonly deregulated in cancers (Guertin & Sabatini, 2007; Villanueva et al., 2008; 
Pópulo, Lopes & Soares, 2012). Rap1 signaling is very important in basic cellular 
functions (e.g., formation, junctions and control of cell adhesions), cellular migration, 
and polarization (Bos, de Rooij & Reedquist, 2001). Rap1 plays key roles during cell 
invasion and metastasis in various cancers (Bos, de Rooij & Reedquist, 2001, p. 1; Zhang 
et al., 2017). p53 signaling pathway is a very important oncogenic pathway, and it can 
regulate apoptosis, the cell cycle and help prevent cancer. P53 protein, a major 
component of p53 signaling pathway, is most frequently altered in cancer (May & May, 
1999).  
Interestingly, Hepatitis C and Hepatitis B pathways are found within the top 50 
pathways in Table 3.1. It is well known that Hepatitis C and Hepatitis B are major risk 
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factors for liver cancer (Beasley, 1988; Chen et al., 2008; Hoshida et al., 2014; Goossens 
& Hoshida, 2015). 
Table 3.1 also includes several pathways that are immune- and inflammatory- related, 
such as Toll-like receptor signaling pathway, HTLV-I infection, Antigen processing and 
presentation and RIG-I-like receptor signaling pathway. It is well documented 
(Grivennikov, Greten & Karin, 2010; Greten, Duffy & Korangy, 2013; Bishayee, 2014; 
Sachdeva, Chawla & Arora, 2015) the fact that the immune system plays a key role in the 
development and progression of cancer, and inflammatory responses play critical roles 
at different stages of cancer development, including initiation, promotion, malignant 
conversion, invasion, and metastasis. In addition, inflammation affects immune 
surveillance and responses to therapy. 
Table 3.1 also includes several other tumor-associated pathways, such as Thyroid 
cancer, Pancreatic cancer, Acute myeloid leukemia and Breast cancer. 
 
3.3.5.  miR2Pathway for cancer subtype analysis 
We then apply miR2Pathway to all the pathways from KEGG comparing normal and 
hepatitis B-induced HCC samples. Table 3.2 lists the top 50 pathways of miRNA-
mediated dysregulation for this analysis. As before, here we only show and analyze the 
results for hepatitis B-induced HCC based on the Pearson’s correlation cutoff of -0.4. 
The other results, based on different Pearson’s correlation cutoff (-0.3, -0.2, -0.1), are 
shown in Table 3.9, Table 3.10 and Table 3.11, respectively.  
 
 
Gene Count(L) T score 
1 Circadian rhythm 31 4.603 
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2 FoxO signaling pathway 126 4.547 
3 Hedgehog signaling pathway 47 4.281 
4 Dorso-ventral axis formation 13 3.619 
5 GnRH signaling pathway 85 3.516 
6 Toll-like receptor signaling pathway 104 2.513 
7 Wnt signaling pathway 137 2.398 
8 MAPK signaling pathway 252 2.388 
9 Rap1 signaling pathway 208 2.379 
10 
Epithelial cell signaling in Helicobacter pylori 
infection 37 
2.083 
11 Shigellosis 51 2.058 
12 Renal cell carcinoma 57 2.043 
13 Notch signaling pathway 48 1.948 
14 Estrogen signaling pathway 89 1.896 
15 Calcium signaling pathway 179 1.796 
16 Hippo signaling pathway -multiple species 29 1.733 
17 Gap junction 88 1.694 
18 Thyroid cancer 28 1.671 
19 
AGE-RAGE signaling pathway in diabetic 
complications 91 
1.629 
20 HTLV-I infection 194 1.612 
21 Bladder cancer 29 1.394 
22 Vascular smooth muscle contraction 114 1.343 
23 TNF signaling pathway 72 1.282 
24 Amyotrophic lateral sclerosis (ALS) 36 1.230 
25 D-Glutamine and D-glutamate metabolism 4 1.181 
26 Cocaine addiction 42 1.179 
27 Sulfur metabolism 9 1.171 
28 MicroRNAs in cancer 262 1.157 
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29 Fc epsilon RI signaling pathway 61 1.143 
30 Long-term depression 59 1.125 
31 Chagas disease (American trypanosomiasis) 89 1.108 
32 Salmonella infection 72 1.098 
33 RNA degradation 18 1.083 
34 Tight junction 125 1.077 
35 Insulin signaling pathway 139 1.010 
36 Leishmaniasis 50 0.986 
37 Viral carcinogenesis 6 0.959 
38 mTOR signaling pathway 144 0.944 
39 Adherens junction 71 0.924 
40 Oocyte meiosis 120 0.916 
41 Bacterial invasion of epithelial cells 57 0.913 
42 Tuberculosis 173 0.912 
43 Vasopressin-regulated water reabsorption 22 0.897 
44 RIG-I-like receptor signaling pathway 48 0.893 
45 
Inflammatory mediator regulation of TRP 
channels 91 
0.879 
46 Retrograde endocannabinoid signaling 59 0.853 
47 Type II diabetes mellitus 47 0.843 
48 Progesterone-mediated oocyte maturation 89 0.826 
49 Thyroid hormone synthesis 46 0.823 
50 Glutamatergic synapse 89 0.815 
Table 3.2. Top 50 pathways ranked by T score comparing normal with hepatitis B-
induced HCC samples based on the Pearson’s correlation cutoff (-0.4). The bold-font 
pathways are non-overlapped with top 50 pathways in Table 3.1. 
 
We find that most of the top 50 pathways from Table 3.2 overlap with the results from 
Table 3.1. The non-common pathways are marked by bold font. A number of these non-
common pathways are theoretically specific for hepatitis B-induced HCC. As we know, 
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hepatitis B-induced HCC is mainly caused by hepatitis B virus, hence, those non-
common pathways might be involved in inflammatory response and immune-system 
related. Interestingly, we find many of the non-common pathways are, indeed, 
inflammation- and immune-system related, such as TNF signaling pathway, Fc epsilon 
RI signaling pathway, Salmonella infection, Viral carcinogenesis, Bacterial invasion of 
epithelial cells, Inflammatory mediator regulation of TRP channels. The selective 
presence of inflammation-related pathways in Table 3.2 suggests that miR2Pathway 
can identify pathways specific for subtypes of HCC. 
We also identify in Table 3.2 several other pathways that are involved in metabolism, 
such as D-Glutamine and D-glutamate metabolism, Sulfur metabolism, Insulin signaling 
pathway and Type II diabetes mellitus. Three of these four pathways are related to 
hepatitis B virus infection. Several studies show that glutamine synthesis and 
metabolism are potential markers of HCC patients infected by hepatitis B (Long et al., 
2010; Li et al., 2015). Very interestingly, some studies show that hepatitis B virus 
infection can contribute to the impairment of insulin signaling (Kim, Kim & Cheong, 
2010; Barthel et al., 2016). It is reported that hepatitis B virus infection rate is higher in 
type II diabetes mellitus patients compared with healthy controls, suggesting that 
hepatitis B virus infection is associated with type II diabetes (Demir et al., 2008).  
We then apply miR2Pathway to analyze other subtypes of HCC, such as hepatitis C-
induced and alcohol-induced HCC. The top 50 pathways are listed in Table 3.4 and 
Table 3.5, respectively. 
In Table 3.4, we include the top 50 pathways from the miR2Pathway analysis of 
hepatitis C-induced HCC based on the Pearson’s correlation cutoff of -0.4. We again find 
that most of the pathways overlap with those from Table 3.1. The non-common 
pathways are theoretically specifically associated with hepatitis C virus (HCV) infection. 
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Interestingly, we discover several non-common pathways also listed in non-common 
pathways of Table 3.2 (hepatitis B-induced HCC), such as D-Glutamine and D-
glutamate metabolism, Bacterial invasion of epithelial cells and Insulin signaling 
pathway. HCV infection might increase glutamine use and dependence, and inhibiting 
glutamine metabolism attenuates HCV infection and the oxidative stress associated with 
HCV infection (Lévy et al., 2017). Some studies show that hepatitis C virus can induce 
insulin resistance (IR), thereby contributing to steatosis, progression of fibrosis and HCC 
(Sheikh et al., 2008; Bose, 2014). Additionally, Bacterial invasion of epithelial cells is an 
inflammation-related pathway, which is specifically associated with this subtype of liver 
cancer. The results for hepatitis C-induced HCC based on different Pearson’s correlation 
cutoffs (-0.3, -0.2, -0.1) can be found in Supplementary Table 3.12, Table 3.13 and 
Table 3.14, respectively. In Table 3.5, we include the top 50 pathways from the 
miR2Pathway analysis of alcohol-induced HCC based on the Pearson’s correlation cutoff 
of -0.4. Again, we find that most of the pathways overlap with Table 3.1. Among the 
non-common pathways between Table 3.5 and Table 3.1, we find many pathways 
associated with inflammation and immune system, such as Pathogenic Escherichia coli 
infection, TNF signaling pathway, B cell receptor signaling pathway and GnRH signaling 
pathway. Some studies have shown that the major mechanisms of alcohol-induced HCC 
include pathways of the immune system and inflammation, reviewed in (Sidharthan & 
Kottilil, 2014). Additionally, very interestingly, Glutamatergic synapse and GABAergic 
synapse are two of non-common pathways for this subtype of HCC. Several studies show 
that alcohol induces many neuroadaptative changes in the CNS involving both 
glutamatergic and GABAergic synaptic transmission (Dildy-Mayfield et al., 1996; 
Lovinger & Roberto, 2013). The results for alcohol-induced HCC based on different 
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Pearson’s correlation cutoff (-0.3, -0.2, -0.1) are shown in Table 3.15, Table 3.16 and 
Table 3.17, respectively. 
 
3.4. Discussion  
We propose a PageRank-based method, called miR2Pathway, to rank disease risk of 
miRNA-mediated biological pathways in HCC. miR2Pathway can help explore how much 
miRNAs differentially influence the activity of biological pathways between two classes 
of phenotypes. The basic idea of PageRank is that the topological importance of a node is 
high in a network if this node has connections with other nodes with high topological 
importance (Page et al., 1999). This can be well applied to miRNA-mediated biological 
pathways. For example, a miRNA has a larger differential influence on a pathway if it 
regulates more genes, particularly hub genes, in the differential network between cases 
and control. Based on this observation, we assess the differential influence of a miRNA 
on the activity of a pathway between normal and HCC through summing up the 
PageRank scores of targeted genes of this miRNA in the corresponding differential 
network, which we call S score. Then, we assess the differential influence of all other 
miRNAs on the activity of this same pathway between normal and HCC. We sum up the 
S scores for all miRNAs to obtain the T score, which measures the total differential 
influence of all the miRNAs on the activity of this pathway. In the same way, we calculate 
corresponding T scores for the total differential influence of all the miRNAs on the 
activity of each pathway. Finally, we rank all pathways by -the T scores, which are 
measures of the degree of miRNA-mediated dysregulation. The miR2Pathway method 
focuses on quantifying the differential effects of a set of miRNA on the activity of 
biological pathways when miRNA-mRNA connections are altered from normal to HCC.   
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Our use of PageRank to study the effect of miRNA-mRNA connections at the pathway 
level is novel. Previous uses of PageRank to study miRNA have been focused on 
clustering analysis for disease subtype classification in cancer (Xu et al., 2016) or 
identification of hub genes in Alzheimer’s Disease (Noh et al., 2014) or ischemic stroke 
(Wang & Cai, 2016). 
In our application of miR2Pathway to study HCC and its subtypes, we find that many 
highly ranked pathways are tumor-associated, such as FoxO signaling pathway, circadian 
rhythm, Wnt signaling pathway, MAPK signaling pathway, mTOR signaling pathway, 
p53 signaling pathway, etc., as well as HCC-specific pathways, such as Hepatitis B, 
Hepatitis C, etc. These results suggest that these important pathways are dysregulated by 
rewired miRNA-mRNA connections in cancer. Besides, many other pathways are 
associated with inflammation, immune system and metabolism, etc., which directly link 
to the occurrence and progression of HCC. In addition, we also find that the “MicroRNAs 
in cancer” pathway is listed in top 50 pathways, which is consistent with the fact that 
miRNAs dysregulate in cancer. Therefore, miR2Pathway can quantify and rank the 
dysregulation of these biological pathways. 
Further, we apply miR2Pathway to analyze three subtypes of HCC: hepatitis B-induced 
HCC, hepatitis C-induced HCC and alcohol-induced HCC. By comparing each subtype of 
HCC with HCC, we check whether the non-common pathways from each subtype of HCC 
are indeed related to each specific subtype of HCC. For hepatitis B-induced HCC and 
hepatitis C-induced HCC, both hepatitis B and hepatitis C viruses are strongly linked to 
inflammation response and immune system. Related to this, among the non-common 
pathways for hepatitis B-induced HCC and hepatitis C-induced HCC, we indeed find 
several inflammation- and immune-related pathways, such as TNF signaling pathway, Fc 
epsilon RI signaling pathway, Salmonella infection, Viral carcinogenesis, Bacterial 
61 
 
invasion of epithelial cells, and Inflammatory mediator regulation of TRP channels. 
Notably, Viral carcinogenesis is strongly associated with virus-induced HCC. Similarly, 
for alcohol-induced HCC, we find several pathways related to immune system and 
inflammation, such as Pathogenic Escherichia coli infection, TNF signaling pathway, B 
cell receptor signaling pathway and GnRH signaling pathway. Previous studies have 
shown that these pathways of immune system and inflammation are related to the major 
mechanisms of alcohol-induced HCC (Sidharthan & Kottilil, 2014).  
 
3.5. Future Directions 
In this study, while we apply miR2pathway to HCC as a proof of concept, we intend to 
study other cancers and diseases to assess the generalizability of our method. We apply 
miR2Pathway to pre-defined biological pathways, from the well-curated KEGG pathway 
database. In addition to this application, miR2Pathway can also be applied to any set of 
genes of interest, such as functional gene networks. Moreover, miR2Pathway could also 
be used to assess differential influence of other regulatory factors, e.g., Transcriptional 
factors (TFs) or circular RNAs, on biological pathways. These could be interesting areas 
to further explore. 
We can further validate the miR2Pathway method using simulated data. First, we select 
a specified pathway (e.g., “MicroRNAs in cancer”). Then, we can simulate miRNA-mRNA 
connections for two networks (e.g., network A and B). To start the simulation, we only 
consider one miRNA and only one miRNA-gene connection is rewired for both the 
network A and B, but it is one rewired miRNA-hub gene connection for the network A, 
while one rewired miRNA-non hub gene connection for the network B. Hence, the 
expected result is that T score of the network A is greater than that of the network B. 
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Then, we apply miR2Pathway to the simulated data to test if the expected result is 
obtained. 
For the PageRank algorithm, we use the default value of damping factor 0.85 in this 
study. However, the value of damping factor might be varying in different cases. Hence, 
we might further use simulation to decide the value of damping factor in different cases. 
This is a very interesting and valuable direction to investigate. 
We obtain ranks of pathways in this study, and we also can further investigate some 
common miRNAs that differentially influence on highly ranked pathway. Those common 
miRNAs also could be drive miRNAs to drive cancer. Extensively, we might further 
quantify each miRNA’s differential influence on each pathway, then sum up total 
differential influence of each miRNA on all pathways, finally, we can rank all miRNAs. 
Those highly ranked miRNAs could be driver miRNAs to drive tumorigenesis. We might 
further investigate those key miRNAs and explore the biology behind those results. 
 
3.6. Conclusion 
In summary, miR2Pathway is a novel method that can be used to assess the total 
differential influence of all miRNAs on the activity of a single pathway between control 
and case. The total differential influence can reflect the degree of miRNA-mediated 
dysregulation of pathways, thereby assessing disease risk of miRNA-mediated biological 
pathways. We apply this method to study HCC and its subtypes and find that a number 
of highly ranked biological pathways are involved in cancer generally and HCC 
specifically. Also, we find many highly ranked pathways are related to inflammation, 
immune system and metabolism, etc., which are directly associated with pathogenesis of 
cancer. miR2Pathway is also able to identify pathways specific to HCC subtypes. 
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Therefore, miR2Pathway is a new method to explore dysregulated pathways by analyzing 
rewired miRNA-mRNA connections.  
 
3.7. Availability 
R software to carry out the miR2Pathway computation is available via 
http://www.dinulab.org/tools. 
 
3.8. Supplementary Materials 
Index Gene ID Gene Symbol PageRank Score Eigenvector Centrality 
1 100302238 MIR103B1 0.003760521 0.041230011 
2 100302282 MIR103B2 0.003760521 0.041230011 
3 406881 MIRLET7A1 0.004941166 0.965748397 
4 406882 MIRLET7A2 0.004941166 0.965748397 
5 406883 MIRLET7A3 0.004941166 0.965748397 
6 406884 MIRLET7B 0.004941166 0.965748397 
7 406885 MIRLET7C 0.005280395 0.370605112 
8 406886 MIRLET7D 0.004941166 0.965748397 
9 406887 MIRLET7E 0.004941166 0.965748397 
10 406888 MIRLET7F1 0.004941166 0.965748397 
11 406889 MIRLET7F2 0.004941166 0.965748397 
12 406890 MIRLET7G 0.004941166 0.965748397 
13 406891 MIRLET7I 0.004941166 0.965748397 
14 406892 MIR100 0.00116434 0.00674992 
15 406893 MIR101-1 0.00300433 0.012099974 
16 406894 MIR101-2 0.00300433 0.012099974 
17 406895 MIR103A1 0.003760521 0.041230011 
18 406896 MIR103A2 0.003760521 0.041230011 
19 406900 MIR106B 0.003280572 2.03E-05 
20 406901 MIR107 0.004914847 0.918751999 
21 406902 MIR10A 0.006916144 0.041096829 
22 406903 MIR10B 0.007923195 0.041464294 
23 406904 MIR1-1 0.004754269 0.001911378 
24 406905 MIR1-2 0.004754269 0.001911378 
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25 406906 MIR122 0.007324118 0 
26 406907 MIR124-1 0.001082422 0.09057311 
27 406908 MIR124-2 0.001082422 0.09057311 
28 406909 MIR124-3 0.001082422 0.09057311 
29 406910 MIR125A 0.004168031 0.118425226 
30 406911 MIR125B1 0.00491907 0.120562116 
31 406912 MIR125B2 0.00491907 0.120562116 
32 406913 MIR126 0.012585104 0 
33 406915 MIR128-1 0.003364869 1.06E-05 
34 406916 MIR128-2 0.003364869 1.06E-05 
35 406917 MIR129-1 0.00471112 0.032238736 
36 406918 MIR129-2 0.00471112 0.032238736 
37 406922 MIR133A1 0.00323224 8.93E-18 
38 406923 MIR133A2 0.00323224 3.06E-17 
39 406925 MIR135A1 0.00323224 4.15E-17 
40 406926 MIR135A2 0.00323224 1.86E-17 
41 406928 MIR137 0.001082422 0.09057311 
42 406933 MIR141 0.003816794 0 
43 406935 MIR143 0.009949437 0.139702723 
44 406937 MIR145 0.004220106 0.034768161 
45 406938 MIR146A 0.007324118 0 
46 406943 MIR152 0.003816794 0 
47 406947 MIR155 0.003816794 0 
48 406948 MIR15A 0.008110503 1.27E-16 
49 406949 MIR15B 0.00413922 1.76E-16 
50 406950 MIR16-1 0.00413922 1.61E-16 
51 406951 MIR16-2 0.00413922 1.93E-16 
52 406952 MIR17 0.003510622 0.001091129 
53 406953 MIR18A 0.002202202 0.095220707 
54 406954 MIR181A2 0.001257143 0.005306336 
55 406955 MIR181B1 0.001257143 0.005306336 
56 406956 MIR181B2 0.001257143 0.005306336 
57 406957 MIR181C 0.001257143 0.005306336 
58 406959 MIR183 0.003816794 4.27E-19 
59 406971 MIR195 0.00846517 0.03836491 
60 406976 MIR199A1 0.003816794 7.95E-18 
61 406977 MIR199A2 0.003816794 0 
62 406979 MIR19A 0.003510622 0.001091129 
63 406980 MIR19B1 0.001755769 0.001081459 
64 406981 MIR19B2 0.001755769 0.001081459 
65 406982 MIR20A 0.007049021 0.001121961 
66 406983 MIR200A 0.005013964 4.34E-07 
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67 406984 MIR200B 0.005013964 4.34E-07 
68 406985 MIR200C 0.005013964 4.34E-07 
69 406988 MIR205 0.004825867 1.19E-08 
70 406991 MIR21 0.017313782 0.007094906 
71 406992 MIR210 0.001652493 1.02E-05 
72 406995 MIR181A1 0.001257143 0.005306336 
73 406996 MIR214 0.001755769 0.001081459 
74 407006 MIR221 0.008132586 0.007539487 
75 407007 MIR222 0.004013834 0.001301028 
76 407008 MIR223 0.002528401 0.006900102 
77 407009 MIR224 0.005570456 6.98E-18 
78 407010 MIR23A 0.004469908 0.008035219 
79 407015 MIR26A1 0.001755769 0.001081459 
80 407016 MIR26A2 0.001755769 0.001081459 
81 407021 MIR29A 0.003268751 0.008938579 
82 407024 MIR29B1 0.003268751 0.008938579 
83 407025 MIR29B2 0.003268751 0.008938579 
84 407026 MIR29C 0.003268751 0.008938579 
85 407029 MIR30A 0.0060909 0.045466633 
86 407030 MIR30B 0.004886337 0.043049027 
87 407031 MIR30C1 0.004886337 0.043049027 
88 407032 MIR30C2 0.004886337 0.043049027 
89 407033 MIR30D 0.0060909 0.045466633 
90 407034 MIR30E 0.0060909 0.045466633 
91 407035 MIR31 0.00907778 0 
92 407036 MIR32 0.003816794 0 
93 407040 MIR34A 0.006423954 0.100639267 
94 407041 MIR34B 0.005274269 0.099747382 
95 407043 MIR7-1 0.004623953 0.030119613 
96 407044 MIR7-2 0.004623953 0.030119613 
97 407045 MIR7-3 0.004623953 0.030119613 
98 407046 MIR9-1 0.002647686 6.42E-18 
99 407047 MIR9-2 0.002647686 1.30E-17 
100 407048 MIR92A1 0.001755769 0.001081459 
101 407049 MIR92A2 0.001755769 0.001081459 
102 407051 MIR9-3 0.002647686 1.68E-17 
103 407055 MIR99A 0.00116434 0.00674992 
104 442890 MIR133B 0.00323224 3.77E-18 
105 442891 MIR135B 0.00323224 2.68E-17 
106 442900 MIR326 0.003888798 0.007364528 
107 442902 MIR330 0.001935407 1.02E-05 
108 442903 MIR331 0.004467768 0.003273428 
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109 442904 MIR335 0.010831442 0 
110 442910 MIR345 0.001284055 0.000807938 
111 442918 MIR373 0.002313655 4.83E-17 
112 554213 MIR449A 0.003816794 0 
113 574411 MIR451A 0.003816794 0 
114 574455 MIR193B 0.003816794 0 
115 574457 MIR181D 0.001257143 0.005306336 
116 574461 MIR520E 0.002313655 6.19E-17 
117 574467 MIR520A 0.002313655 5.67E-17 
118 574473 MIR520B 0.002313655 4.58E-17 
119 574476 MIR520C 0.002313655 5.93E-17 
120 574484 MIR520G 0.002313655 5.54E-17 
121 574493 MIR520H 0.002313655 5.81E-17 
122 693187 MIR602 0.001415719 0.000738215 
123 2261 FGFR3 0.013925189 0.071701442 
124 23405 DICER1 0.003083264 0.102016071 
125 5578 PRKCA 0.011745384 0.08290846 
126 5579 PRKCB 0.011745384 0.08290846 
127 5582 PRKCG 0.011745384 0.08290846 
128 9252 RPS6KA5 0.002703481 0.015525449 
129 1021 CDK6 0.009598166 0.962118469 
130 10642 IGF2BP1 0.004390693 0.909148282 
131 131405 TRIM71 0.004390693 0.909148282 
132 3265 HRAS 0.005031883 0.944036769 
133 3845 KRAS 0.008403462 1 
134 4893 NRAS 0.005031883 0.944036769 
135 8091 HMGA2 0.005031883 0.944036769 
136 993 CDC25A 0.004390693 0.909148282 
137 994 CDC25B 0.004390693 0.909148282 
138 995 CDC25C 0.004390693 0.909148282 
139 4609 MYC 0.00121371 0.034888487 
140 6774 STAT3 0.00121371 0.034888487 
141 836 CASP3 0.00121371 0.034888487 
142 2146 EZH2 0.001849359 0.002278165 
143 5335 PLCG1 0.004960059 0.027276558 
144 5336 PLCG2 0.004960059 0.027276558 
145 1026 CDKN1A 0.003165096 0.000107535 
146 1869 E2F1 0.004810192 0.000108497 
147 11186 RASSF1 0.002975999 0.007841737 
148 2885 GRB2 0.003570894 0.017453747 
149 4193 MDM2 0.002760166 0.008482004 
150 4194 MDM4 0.002916767 0.013842103 
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151 472 ATM 0.015303357 0.056366883 
152 5594 MAPK1 0.00337662 0.012140315 
153 3236 HOXD10 0.001184766 0.003903417 
154 27086 FOXP1 0.002593084 0.000359871 
155 4233 MET 0.004120323 0.01922412 
156 5292 PIM1 0.002593084 0.000359871 
157 9759 HDAC4 0.002593084 0.000359871 
158 3162 HMOX1 0.002647686 1.37E-17 
159 6541 SLC7A1 0.002647686 1.74E-17 
160 900 CCNG1 0.002647686 1.00E-17 
161 1029 CDKN2A 0.002357622 0.033847716 
162 1956 EGFR 0.00463991 0.045627078 
163 2064 ERBB2 0.003623489 0.034155874 
164 7157 TP53 0.007193432 0.072647189 
165 578 BAK1 0.00176715 0.022699254 
166 1398 CRK 0.002355409 5.34E-17 
167 1399 CRKL 0.002355409 3.51E-17 
168 5290 PIK3CA 0.002355409 6.05E-17 
169 5296 PIK3R2 0.002355409 4.82E-17 
170 7422 VEGFA 0.002355409 5.79E-17 
171 85414 SLC45A3 0.002355409 4.76E-17 
172 100532731 
COMMD3-
BMI1 0.0050364 2.12E-06 
173 1871 E2F3 0.005082231 0.000108583 
174 648 BMI1 0.0050364 2.12E-06 
175 399694 SHC4 0.001716648 0.006069861 
176 4170 MCL1 0.004693625 0 
177 599 BCL2L2 0.004693625 1.61E-17 
178 10297 APC2 0.004693625 2.37E-17 
179 324 APC 0.004693625 0 
180 7042 TGFB2 0.003816794 0 
181 1788 DNMT3A 0.004001498 0.016517394 
182 5155 PDGFB 0.001223059 0.013151509 
183 5159 PDGFRB 0.001223059 0.013151509 
184 5598 MAPK7 0.001223059 0.013151509 
185 5894 RAF1 0.001877186 0.016763153 
186 6654 SOS1 0.001877186 0.016763153 
187 6655 SOS2 0.001877186 0.016763153 
188 3667 IRS1 0.001170367 0.003273049 
189 4325 MMP16 0.002647686 8.78E-18 
190 6093 ROCK1 0.002647686 1.70E-17 
191 672 BRCA1 0.002647686 1.28E-17 
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192 1786 DNMT1 0.003816794 0 
193 8651 SOCS1 0.003816794 0 
194 595 CCND1 0.004196118 1.16E-16 
195 596 BCL2 0.001557366 6.87E-17 
196 7473 WNT3 0.001557366 6.90E-17 
197 894 CCND2 0.004196118 1.97E-16 
198 89780 WNT3A 0.001557366 7.51E-17 
199 898 CCNE1 0.004196118 1.64E-16 
200 9134 CCNE2 0.004196118 1.56E-16 
201 5728 PTEN 0.019488814 0.011487865 
202 7431 VIM 0.002064533 0.000102718 
203 7430 EZR 0.003816794 0 
204 5604 MAP2K1 0.001226646 0.003611644 
205 5605 MAP2K2 0.001226646 0.003611644 
206 3551 IKBKB 0.003816794 1.36E-17 
207 5743 PTGS2 0.003816794 7.34E-18 
208 7057 THBS1 0.002064533 0.000102718 
209 1870 E2F2 0.001770853 0.000105621 
210 23414 ZFPM2 0.003129641 1.23E-07 
211 6935 ZEB1 0.003129641 1.23E-07 
212 9839 ZEB2 0.00449697 1.24E-07 
213 2065 ERBB3 0.001939848 1.12E-09 
214 5581 PRKCE 0.001939848 1.12E-09 
215 10253 SPRY2 0.001798912 0.000667909 
216 27250 PDCD4 0.001798912 0.000667909 
217 3190 HNRNPK 0.001798912 0.000667909 
218 4082 MARCKS 0.001798912 0.000667909 
219 5268 SERPINB5 0.001798912 0.000667909 
220 659 BMPR2 0.001798912 0.000667909 
221 7078 TIMP3 0.003923693 0.001500149 
222 7168 TPM1 0.001798912 0.000667909 
223 8434 RECK 0.001798912 0.000667909 
224 8626 TP63 0.001798912 0.000667909 
225 1027 CDKN1B 0.0026973 0.000832239 
226 54541 DDIT4 0.001560047 0.000709762 
227 90427 BMF 0.001560047 0.000709762 
228 3925 STMN1 0.00164709 0.00064957 
229 10298 PAK4 0.002939963 1.98E-17 
230 4318 MMP9 0.002939963 1.40E-17 
231 27165 GLS2 0.001522375 0.00075643 
232 2744 GLS 0.001522375 0.00075643 
233 1789 DNMT3B 0.003350958 0.003365884 
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234 5156 PDGFRA 0.003350958 0.003365884 
235 3690 ITGB3 0.002125698 0.012840584 
236 5154 PDGFA 0.003683218 0.024998393 
237 7329 UBE2I 0.002125698 0.012840584 
238 3678 ITGA5 0.002501547 3.23E-17 
239 387 RHOA 0.002501547 3.96E-17 
240 5962 RDX 0.002501547 3.55E-17 
241 7976 FZD3 0.002501547 2.79E-17 
242 10018 BCL2L11 0.003816794 0 
243 23411 SIRT1 0.001352571 0.009474105 
244 4851 NOTCH1 0.002926128 0.01955754 
245 4853 NOTCH2 0.002926128 0.01955754 
246 4854 NOTCH3 0.002926128 0.01955754 
247 4855 NOTCH4 0.002926128 0.01955754 
248 4363 ABCC1 0.003348406 0.008582372 
249 6464 SHC1 0.002256959 0.008506313 
250 8660 IRS2 0.002256959 0.008506313 
251 4790 NFKB1 0.007324118 0 
252 113130 CDCA5 0.001838387 0.000308158 
253 9493 KIF23 0.001838387 0.000308158 
254 3371 TNC 0.002413864 6.88E-17 
255 63923 TNN 0.002413864 5.51E-17 
256 6659 SOX4 0.002413864 5.43E-17 
257 7143 TNR 0.002413864 5.69E-17 
258 7148 TNXB 0.002413864 3.99E-17 
259 960 CD44 0.014338766 0 
260 3065 HDAC1 0.003816794 0 
261 5243 ABCB1 0.003816794 0 
262 5328 PLAU 0.003816794 0 
Table 3.3. The information of the 262 genes in the “MicroRNAs in cancer” pathway. We 
consolidate the information as shown in this table: (1) Index (1-262) (2) Gene ID (3) 
Gene Symbol (4) The corresponding PageRank scores of each gene (5) The 
corresponding Eigenvector centrality of genes in this pathway, which is computed by a 
built-in function in the igraph R package called eigen_centrality(). 
 
 
 
Gene Count(L) T score 
1 FoxO signaling pathway 126 2.519 
2 Rap1 signaling pathway 208 1.523 
3 Hedgehog signaling pathway 47 1.248 
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4 MicroRNAs in cancer 262 0.797 
5 Vascular smooth muscle contraction 114 0.790 
6 Hippo signaling pathway -multiple species 29 0.776 
7 Circadian rhythm 31 0.753 
8 Renal cell carcinoma 57 0.725 
9 Wnt signaling pathway 137 0.707 
10 mTOR signaling pathway 144 0.607 
11 Progesterone-mediated oocyte maturation 89 0.604 
12 Shigellosis 51 0.602 
13 D-Glutamine and D-glutamate metabolism 4 0.590 
14 Inflammatory bowel disease (IBD) 48 0.582 
15 MAPK signaling pathway 252 0.574 
16 AGE-RAGE signaling pathway in diabetic complications 91 0.527 
17 Insulin resistance 94 0.511 
18 Adipocytokine signaling pathway 63 0.510 
19 RNA degradation 18 0.488 
20 Estrogen signaling pathway 89 0.451 
21 Pancreatic cancer 65 0.439 
22 Bacterial invasion of epithelial cells 57 0.438 
23 Nitrogen metabolism 4 0.435 
24 Steroid biosynthesis 20 0.426 
25 Cocaine addiction 42 0.421 
26 HTLV-I infection 194 0.415 
27 Notch signaling pathway 48 0.413 
28 alpha-Linolenic acid metabolism 25 0.408 
29 Bladder cancer 29 0.401 
30 Cytosolic DNA-sensing pathway 21 0.398 
31 Oocyte meiosis 120 0.392 
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32 Thyroid cancer 28 0.386 
33 Insulin signaling pathway 139 0.377 
34 Vasopressin-regulated water reabsorption 22 0.374 
35 Toll-like receptor signaling pathway 104 0.355 
36 Leukocyte transendothelial migration 85 0.348 
37 Parkinson's disease 29 0.345 
38 Epithelial cell signaling in Helicobacter pylori infection 37 0.344 
39 Calcium signaling pathway 179 0.341 
40 Amyotrophic lateral sclerosis (ALS) 36 0.328 
41 Breast cancer 143 0.315 
42 Long-term potentiation 67 0.314 
43 
Signaling pathways regulating pluripotency of 
stem cells 112 
0.297 
44 Axon guidance 167 0.294 
45 Long-term depression 59 0.290 
46 GnRH signaling pathway 85 0.288 
47 Proximal tubule bicarbonate reclamation 7 0.286 
48 Hepatitis C 97 0.282 
49 Cell cycle 124 0.279 
50 Tuberculosis 173 0.276 
Table 3.4. Top 50 pathways ranked by T score comparing normal with hepatitis C-
induced HCC samples based on the Pearson’s correlation cutoff (-0.4). The bold-font 
pathways are non-overlapped with top 50 pathways in Table 3.1. 
 
 
 
 
Gene Count(L) T score 
1 FoxO signaling pathway 126 0.723 
2 alpha-Linolenic acid metabolism 25 0.408 
3 Notch signaling pathway 48 0.354 
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4 Hippo signaling pathway -multiple species 29 0.333 
5 Hedgehog signaling pathway 47 0.322 
6 Cytosolic DNA-sensing pathway 21 0.265 
7 Circadian rhythm 31 0.251 
8 Inflammatory bowel disease (IBD) 48 0.242 
9 Toll-like receptor signaling pathway 104 0.237 
10 Shigellosis 51 0.222 
11 RNA degradation 18 0.217 
12 Epithelial cell signaling in Helicobacter pylori infection 37 0.191 
13 MAPK signaling pathway 252 0.167 
14 AGE-RAGE signaling pathway in diabetic complications 91 0.162 
15 mTOR signaling pathway 144 0.159 
16 Progesterone-mediated oocyte maturation 89 0.151 
17 HTLV-I infection 194 0.150 
18 Oocyte meiosis 120 0.143 
19 Insulin resistance 94 0.132 
20 Adipocytokine signaling pathway 63 0.128 
21 Rap1 signaling pathway 208 0.127 
22 Wnt signaling pathway 137 0.126 
23 Chagas disease (American trypanosomiasis) 89 0.117 
24 Hepatitis C 97 0.114 
25 MicroRNAs in cancer 262 0.111 
26 Long-term depression 59 0.109 
27 Pancreatic cancer 65 0.107 
28 Leishmaniasis 50 0.101 
29 Acute myeloid leukemia 57 0.100 
30 Glyoxylate and dicarboxylate metabolism 26 0.097 
31 Pantothenate and CoA biosynthesis 16 0.094 
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32 Morphine addiction 54 0.091 
33 Retrograde endocannabinoid signaling 59 0.091 
34 Hepatitis B 134 0.087 
35 Toxoplasmosis 93 0.086 
36 Herpes simplex infection 104 0.086 
37 Long-term potentiation 67 0.085 
38 Estrogen signaling pathway 89 0.082 
39 RIG-I-like receptor signaling pathway 48 0.082 
40 Glutamatergic synapse 89 0.080 
41 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 10 
0.077 
42 GABAergic synapse 66 0.075 
43 Osteoclast differentiation 123 0.069 
44 Pathogenic Escherichia coli infection 40 0.068 
45 Bladder cancer 29 0.067 
46 Thyroid cancer 28 0.064 
47 TNF signaling pathway 72 0.064 
48 B cell receptor signaling pathway 70 0.062 
49 GnRH signaling pathway 85 0.062 
50 Vascular smooth muscle contraction 114 0.061 
Table 3.5. Top 50 pathways ranked by T score comparing normal with alcohol-induced 
HCC samples based on the Pearson’s correlation cutoff (-0.4). The bold-font pathways 
are non-overlapped with top 50 pathways in Table 3.1. 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 4.769631872 
2 Cocaine addiction 42 3.790618613 
3 Circadian rhythm 31 3.59848471 
4 Hedgehog signaling pathway 47 3.247139618 
5 Dorso-ventral axis formation 13 2.832281658 
6 Notch signaling pathway 48 2.715229884 
7 Rap1 signaling pathway 208 2.696510591 
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8 Hippo signaling pathway -multiple species 29 2.494673335 
9 RNA degradation 18 2.383674555 
10 Estrogen signaling pathway 89 2.166927109 
11 Shigellosis 51 1.868168859 
12 Calcium signaling pathway 179 1.84637558 
13 Wnt signaling pathway 137 1.792202489 
14 Vascular smooth muscle contraction 114 1.738601876 
15 Vasopressin-regulated water reabsorption 22 1.719795843 
16 MAPK signaling pathway 252 1.5537004 
17 HTLV-I infection 194 1.531839998 
18 Insulin resistance 94 1.419444038 
19 Glutamatergic synapse 89 1.405421018 
20 mTOR signaling pathway 144 1.403923184 
21 Bacterial invasion of epithelial cells 57 1.388448828 
22 Renal cell carcinoma 57 1.384068279 
23 Thyroid hormone synthesis 46 1.283676831 
24 Thyroid cancer 28 1.221223406 
25 MicroRNAs in cancer 262 1.206816051 
26 Long-term depression 59 1.19784699 
27 Huntington's disease 27 1.149259079 
28 GnRH signaling pathway 85 1.13073527 
29 Gap junction 88 1.123257389 
30 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 10 1.078378378 
31 Progesterone-mediated oocyte maturation 89 1.055398393 
32 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.054079381 
33 Retrograde endocannabinoid signaling 59 1.034413371 
34 Fatty acid biosynthesis 13 1.022351755 
35 Pancreatic secretion 30 0.987496865 
36 Oocyte meiosis 120 0.986979296 
37 Amyotrophic lateral sclerosis (ALS) 36 0.983800494 
38 Aldosterone synthesis and secretion 65 0.976533251 
39 Maturity onset diabetes of the young 24 0.963574619 
40 Viral carcinogenesis 6 0.959459459 
41 
Signaling pathways regulating pluripotency 
of stem cells 112 0.954367248 
42 Long-term potentiation 67 0.942978837 
43 Toll-like receptor signaling pathway 104 0.933864231 
44 Melanogenesis 101 0.924727007 
45 Insulin secretion 54 0.900427584 
46 Morphine addiction 54 0.889599249 
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47 
Epithelial cell signaling in Helicobacter 
pylori infection 37 0.880104219 
48 Cytosolic DNA-sensing pathway 21 0.862616564 
49 Inflammatory bowel disease (IBD) 48 0.858072477 
50 Alzheimer's disease 48 0.843041679 
Table 3.6. Top 50 pathways ranked by T score comparing normal with HCC samples 
based on the Pearson’s correlation cutoff (-0.3). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 7.511864547 
2 Cocaine addiction 42 6.038087082 
3 Dorso-ventral axis formation 13 5.664563315 
4 Circadian rhythm 31 5.439569911 
5 Hedgehog signaling pathway 47 4.77862805 
6 Rap1 signaling pathway 208 4.307901326 
7 Hippo signaling pathway -multiple species 29 3.82516578 
8 Estrogen signaling pathway 89 3.581660156 
9 Notch signaling pathway 48 3.423550724 
10 RNA degradation 18 3.19629088 
11 Calcium signaling pathway 179 3.112523145 
12 Wnt signaling pathway 137 2.85237861 
13 Vasopressin-regulated water reabsorption 22 2.727502482 
14 Shigellosis 51 2.659765832 
15 Vascular smooth muscle contraction 114 2.65643198 
16 Renal cell carcinoma 57 2.636320531 
17 Thyroid cancer 28 2.442446812 
18 MAPK signaling pathway 252 2.386014506 
19 HTLV-I infection 194 2.26229856 
20 Glutamatergic synapse 89 2.203955688 
21 Thyroid hormone synthesis 46 2.166772169 
22 mTOR signaling pathway 144 2.153472537 
23 
AGE-RAGE signaling pathway in diabetic 
complications 91 2.108158762 
24 Insulin resistance 94 2.055957205 
25 Long-term depression 59 2.032710043 
26 GnRH signaling pathway 85 2.014764663 
27 Huntington's disease 27 1.838814526 
28 Gap junction 88 1.82767304 
29 Bacterial invasion of epithelial cells 57 1.826906352 
30 Pancreatic secretion 30 1.777494357 
31 MicroRNAs in cancer 262 1.724442638 
32 Amyotrophic lateral sclerosis (ALS) 36 1.680659178 
76 
 
33 Maturity onset diabetes of the young 24 1.651842204 
34 Aldosterone synthesis and secretion 65 1.647899861 
35 Progesterone-mediated oocyte maturation 89 1.622806724 
36 Retrograde endocannabinoid signaling 59 1.578841462 
37 Tight junction 125 1.577960616 
38 Insulin secretion 54 1.560946654 
39 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 10 1.540540541 
40 Melanogenesis 101 1.491495172 
41 mRNA surveillance pathway 70 1.486293436 
42 
Signaling pathways regulating pluripotency 
of stem cells 112 1.476804152 
43 Bladder cancer 29 1.470584223 
44 Long-term potentiation 67 1.450736673 
45 Insulin signaling pathway 139 1.44934286 
46 Salivary secretion 48 1.401201983 
47 Morphine addiction 54 1.391424466 
48 Oocyte meiosis 120 1.379392752 
49 Toll-like receptor signaling pathway 104 1.377522425 
50 Transcriptional misregulation in cancer 19 1.315789474 
Table 3.7. Top 50 pathways ranked by T score comparing normal with HCC samples 
based on the Pearson’s correlation cutoff (-0.2). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 7.511864547 
2 Cocaine addiction 42 6.038087082 
3 Dorso-ventral axis formation 13 5.664563315 
4 Circadian rhythm 31 5.439569911 
5 Hedgehog signaling pathway 47 4.77862805 
6 Rap1 signaling pathway 208 4.307901326 
7 Hippo signaling pathway -multiple species 29 3.82516578 
8 Estrogen signaling pathway 89 3.581660156 
9 Notch signaling pathway 48 3.423550724 
10 RNA degradation 18 3.19629088 
11 Calcium signaling pathway 179 3.112523145 
12 Wnt signaling pathway 137 2.85237861 
13 Vasopressin-regulated water reabsorption 22 2.727502482 
14 Shigellosis 51 2.659765832 
15 Vascular smooth muscle contraction 114 2.65643198 
16 Renal cell carcinoma 57 2.636320531 
17 Thyroid cancer 28 2.442446812 
18 MAPK signaling pathway 252 2.386014506 
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19 HTLV-I infection 194 2.26229856 
20 Glutamatergic synapse 89 2.203955688 
21 Thyroid hormone synthesis 46 2.166772169 
22 mTOR signaling pathway 144 2.153472537 
23 
AGE-RAGE signaling pathway in diabetic 
complications 91 2.108158762 
24 Insulin resistance 94 2.055957205 
25 Long-term depression 59 2.032710043 
26 GnRH signaling pathway 85 2.014764663 
27 Huntington's disease 27 1.838814526 
28 Gap junction 88 1.82767304 
29 Bacterial invasion of epithelial cells 57 1.826906352 
30 Pancreatic secretion 30 1.777494357 
31 MicroRNAs in cancer 262 1.724442638 
32 Amyotrophic lateral sclerosis (ALS) 36 1.680659178 
33 Maturity onset diabetes of the young 24 1.651842204 
34 Aldosterone synthesis and secretion 65 1.647899861 
35 Progesterone-mediated oocyte maturation 89 1.622806724 
36 Retrograde endocannabinoid signaling 59 1.578841462 
37 Tight junction 125 1.577960616 
38 Insulin secretion 54 1.560946654 
39 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 10 1.540540541 
40 Melanogenesis 101 1.491495172 
41 mRNA surveillance pathway 70 1.486293436 
42 
Signaling pathways regulating pluripotency 
of stem cells 112 1.476804152 
43 Bladder cancer 29 1.470584223 
44 Long-term potentiation 67 1.450736673 
45 Insulin signaling pathway 139 1.44934286 
46 Salivary secretion 48 1.401201983 
47 Morphine addiction 54 1.391424466 
48 Oocyte meiosis 120 1.379392752 
49 Toll-like receptor signaling pathway 104 1.377522425 
50 Transcriptional misregulation in cancer 19 1.315789474 
Table 3.8. Top 50 pathways ranked by T score comparing normal with HCC samples 
based on the Pearson’s correlation cutoff (-0.1). 
 
  
Gene 
Count(L) T score 
1 Circadian rhythm 31 4.602713001 
2 FoxO signaling pathway 126 4.546560009 
3 Hedgehog signaling pathway 47 4.280954331 
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4 Dorso-ventral axis formation 13 3.619026562 
5 GnRH signaling pathway 85 3.515558749 
6 Toll-like receptor signaling pathway 104 2.51299444 
7 Wnt signaling pathway 137 2.398017415 
8 MAPK signaling pathway 252 2.387515249 
9 Rap1 signaling pathway 208 2.379274051 
10 
Epithelial cell signaling in Helicobacter 
pylori infection 37 2.082740987 
11 Shigellosis 51 2.058152132 
12 Renal cell carcinoma 57 2.043148412 
13 Notch signaling pathway 48 1.947882308 
14 Estrogen signaling pathway 89 1.895632946 
15 Calcium signaling pathway 179 1.795913644 
16 Hippo signaling pathway -multiple species 29 1.732928622 
17 Gap junction 88 1.694405214 
18 Thyroid cancer 28 1.671147819 
19 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.628931462 
20 HTLV-I infection 194 1.612144396 
21 Bladder cancer 29 1.394263792 
22 Vascular smooth muscle contraction 114 1.343415467 
23 TNF signaling pathway 72 1.282307963 
24 Amyotrophic lateral sclerosis (ALS) 36 1.229750618 
25 D-Glutamine and D-glutamate metabolism 4 1.180851064 
26 Cocaine addiction 42 1.179303568 
27 Sulfur metabolism 9 1.171049088 
28 MicroRNAs in cancer 262 1.157281824 
29 Fc epsilon RI signaling pathway 61 1.142588348 
30 Long-term depression 59 1.125250203 
31 Chagas disease (American trypanosomiasis) 89 1.10760282 
32 Salmonella infection 72 1.098184761 
33 RNA degradation 18 1.083488434 
34 Tight junction 125 1.077236311 
35 Insulin signaling pathway 139 1.009797097 
36 Leishmaniasis 50 0.985719996 
37 Viral carcinogenesis 6 0.959459459 
38 mTOR signaling pathway 144 0.94384078 
39 Adherens junction 71 0.924425552 
40 Oocyte meiosis 120 0.915631395 
41 Bacterial invasion of epithelial cells 57 0.913453176 
42 Tuberculosis 173 0.91194481 
43 Vasopressin-regulated water reabsorption 22 0.897284788 
44 RIG-I-like receptor signaling pathway 48 0.892891945 
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45 
Inflammatory mediator regulation of TRP 
channels 91 0.878612581 
46 Retrograde endocannabinoid signaling 59 0.852937341 
47 Type II diabetes mellitus 47 0.843394635 
48 Progesterone-mediated oocyte maturation 89 0.826138972 
49 Thyroid hormone synthesis 46 0.822674589 
50 Glutamatergic synapse 89 0.814505363 
Table 3.9. Top 50 pathways ranked by T score comparing normal with hepatitis B-
induced HCC samples based on the Pearson’s correlation cutoff (-0.3). 
 
  
Gene 
Count(L) T score 
1 Circadian rhythm 31 4.602713001 
2 FoxO signaling pathway 126 4.546560009 
3 Hedgehog signaling pathway 47 4.280954331 
4 Dorso-ventral axis formation 13 3.619026562 
5 GnRH signaling pathway 85 3.515558749 
6 Toll-like receptor signaling pathway 104 2.51299444 
7 Wnt signaling pathway 137 2.398017415 
8 MAPK signaling pathway 252 2.387515249 
9 Rap1 signaling pathway 208 2.379274051 
10 
Epithelial cell signaling in Helicobacter 
pylori infection 37 2.082740987 
11 Shigellosis 51 2.058152132 
12 Renal cell carcinoma 57 2.043148412 
13 Notch signaling pathway 48 1.947882308 
14 Estrogen signaling pathway 89 1.895632946 
15 Calcium signaling pathway 179 1.795913644 
16 Hippo signaling pathway -multiple species 29 1.732928622 
17 Gap junction 88 1.694405214 
18 Thyroid cancer 28 1.671147819 
19 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.628931462 
20 HTLV-I infection 194 1.612144396 
21 Bladder cancer 29 1.394263792 
22 Vascular smooth muscle contraction 114 1.343415467 
23 TNF signaling pathway 72 1.282307963 
24 Amyotrophic lateral sclerosis (ALS) 36 1.229750618 
25 D-Glutamine and D-glutamate metabolism 4 1.180851064 
26 Cocaine addiction 42 1.179303568 
27 Sulfur metabolism 9 1.171049088 
28 MicroRNAs in cancer 262 1.157281824 
29 Fc epsilon RI signaling pathway 61 1.142588348 
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30 Long-term depression 59 1.125250203 
31 Chagas disease (American trypanosomiasis) 89 1.10760282 
32 Salmonella infection 72 1.098184761 
33 RNA degradation 18 1.083488434 
34 Tight junction 125 1.077236311 
35 Insulin signaling pathway 139 1.009797097 
36 Leishmaniasis 50 0.985719996 
37 Viral carcinogenesis 6 0.959459459 
38 mTOR signaling pathway 144 0.94384078 
39 Adherens junction 71 0.924425552 
40 Oocyte meiosis 120 0.915631395 
41 Bacterial invasion of epithelial cells 57 0.913453176 
42 Tuberculosis 173 0.91194481 
43 Vasopressin-regulated water reabsorption 22 0.897284788 
44 RIG-I-like receptor signaling pathway 48 0.892891945 
45 
Inflammatory mediator regulation of TRP 
channels 91 0.878612581 
46 Retrograde endocannabinoid signaling 59 0.852937341 
47 Type II diabetes mellitus 47 0.843394635 
48 Progesterone-mediated oocyte maturation 89 0.826138972 
49 Thyroid hormone synthesis 46 0.822674589 
50 Glutamatergic synapse 89 0.814505363 
Table 3.10. Top 50 pathways ranked by T score comparing normal with hepatitis B-
induced HCC samples based on the Pearson’s correlation cutoff (-0.2). 
 
  
Gene 
Count(L) T score 
1 Circadian rhythm 31 4.602713001 
2 FoxO signaling pathway 126 4.546560009 
3 Hedgehog signaling pathway 47 4.280954331 
4 Dorso-ventral axis formation 13 3.619026562 
5 GnRH signaling pathway 85 3.515558749 
6 Toll-like receptor signaling pathway 104 2.51299444 
7 Wnt signaling pathway 137 2.398017415 
8 MAPK signaling pathway 252 2.387515249 
9 Rap1 signaling pathway 208 2.379274051 
10 
Epithelial cell signaling in Helicobacter 
pylori infection 37 2.082740987 
11 Shigellosis 51 2.058152132 
12 Renal cell carcinoma 57 2.043148412 
13 Notch signaling pathway 48 1.947882308 
14 Estrogen signaling pathway 89 1.895632946 
15 Calcium signaling pathway 179 1.795913644 
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16 Hippo signaling pathway -multiple species 29 1.732928622 
17 Gap junction 88 1.694405214 
18 Thyroid cancer 28 1.671147819 
19 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.628931462 
20 HTLV-I infection 194 1.612144396 
21 Bladder cancer 29 1.394263792 
22 Vascular smooth muscle contraction 114 1.343415467 
23 TNF signaling pathway 72 1.282307963 
24 Amyotrophic lateral sclerosis (ALS) 36 1.229750618 
25 D-Glutamine and D-glutamate metabolism 4 1.180851064 
26 Cocaine addiction 42 1.179303568 
27 Sulfur metabolism 9 1.171049088 
28 MicroRNAs in cancer 262 1.157281824 
29 Fc epsilon RI signaling pathway 61 1.142588348 
30 Long-term depression 59 1.125250203 
31 Chagas disease (American trypanosomiasis) 89 1.10760282 
32 Salmonella infection 72 1.098184761 
33 RNA degradation 18 1.083488434 
34 Tight junction 125 1.077236311 
35 Insulin signaling pathway 139 1.009797097 
36 Leishmaniasis 50 0.985719996 
37 Viral carcinogenesis 6 0.959459459 
38 mTOR signaling pathway 144 0.94384078 
39 Adherens junction 71 0.924425552 
40 Oocyte meiosis 120 0.915631395 
41 Bacterial invasion of epithelial cells 57 0.913453176 
42 Tuberculosis 173 0.91194481 
43 Vasopressin-regulated water reabsorption 22 0.897284788 
44 RIG-I-like receptor signaling pathway 48 0.892891945 
45 
Inflammatory mediator regulation of TRP 
channels 91 0.878612581 
46 Retrograde endocannabinoid signaling 59 0.852937341 
47 Type II diabetes mellitus 47 0.843394635 
48 Progesterone-mediated oocyte maturation 89 0.826138972 
49 Thyroid hormone synthesis 46 0.822674589 
50 Glutamatergic synapse 89 0.814505363 
Table 3.11. Top 50 pathways ranked by T score comparing normal with hepatitis B-
induced HCC samples based on the Pearson’s correlation cutoff (-0.1). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 5.046943443 
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2 Rap1 signaling pathway 208 4.065776968 
3 Hedgehog signaling pathway 47 3.836894713 
4 Cocaine addiction 42 2.779786983 
5 Circadian rhythm 31 2.594256419 
6 Wnt signaling pathway 137 2.398017415 
7 Hippo signaling pathway -multiple species 29 2.342737659 
8 RNA degradation 18 1.950279181 
9 Renal cell carcinoma 57 1.911332385 
10 Notch signaling pathway 48 1.888855572 
11 Vascular smooth muscle contraction 114 1.796469051 
12 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.74328513 
13 Shigellosis 51 1.741513343 
14 MAPK signaling pathway 252 1.720852339 
15 Bacterial invasion of epithelial cells 57 1.717291971 
16 Steroid biosynthesis 20 1.622392948 
17 mTOR signaling pathway 144 1.618051267 
18 Estrogen signaling pathway 89 1.608441789 
19 Thyroid cancer 28 1.606872903 
20 Dorso-ventral axis formation 13 1.57348981 
21 Calcium signaling pathway 179 1.532591743 
22 MicroRNAs in cancer 262 1.506902683 
23 Parkinson's disease 29 1.381536755 
24 Progesterone-mediated oocyte maturation 89 1.343600254 
25 Insulin resistance 94 1.285414079 
26 Vasopressin-regulated water reabsorption 22 1.271153449 
27 HTLV-I infection 194 1.217230571 
28 Tight junction 125 1.212432605 
29 Bladder cancer 29 1.203205273 
30 Inflammatory bowel disease (IBD) 48 1.148826083 
31 Leukocyte transendothelial migration 85 1.128676988 
32 
Epithelial cell signaling in Helicobacter 
pylori infection 37 1.109696624 
33 Insulin signaling pathway 139 1.055000849 
34 Adipocytokine signaling pathway 63 1.046300074 
35 Amyotrophic lateral sclerosis (ALS) 36 0.983800494 
36 GnRH signaling pathway 85 0.966264685 
37 Breast cancer 143 0.943208322 
38 Oocyte meiosis 120 0.927522712 
39 Adherens junction 71 0.904756923 
40 Long-term potentiation 67 0.873254968 
41 Axon guidance 167 0.867502498 
42 Cytosolic DNA-sensing pathway 21 0.862616564 
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43 ECM-receptor interaction 81 0.858243412 
44 Toll-like receptor signaling pathway 104 0.851435884 
45 Long-term depression 59 0.834863053 
46 alpha-Linolenic acid metabolism 25 0.815135135 
47 Pancreatic cancer 65 0.80634025 
48 Gap junction 88 0.799606955 
49 
Signaling pathways regulating pluripotency 
of stem cells 112 0.783109171 
50 Alzheimer's disease 48 0.771233168 
Table 3.12. Top 50 pathways ranked by T score comparing normal with hepatitis C-
induced HCC samples based on the Pearson’s correlation cutoff (-0.3). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 5.046943443 
2 Rap1 signaling pathway 208 4.065776968 
3 Hedgehog signaling pathway 47 3.836894713 
4 Cocaine addiction 42 2.779786983 
5 Circadian rhythm 31 2.594256419 
6 Wnt signaling pathway 137 2.398017415 
7 Hippo signaling pathway -multiple species 29 2.342737659 
8 RNA degradation 18 1.950279181 
9 Renal cell carcinoma 57 1.911332385 
10 Notch signaling pathway 48 1.888855572 
11 Vascular smooth muscle contraction 114 1.796469051 
12 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.74328513 
13 Shigellosis 51 1.741513343 
14 MAPK signaling pathway 252 1.720852339 
15 Bacterial invasion of epithelial cells 57 1.717291971 
16 Steroid biosynthesis 20 1.622392948 
17 mTOR signaling pathway 144 1.618051267 
18 Estrogen signaling pathway 89 1.608441789 
19 Thyroid cancer 28 1.606872903 
20 Dorso-ventral axis formation 13 1.57348981 
21 Calcium signaling pathway 179 1.532591743 
22 MicroRNAs in cancer 262 1.506902683 
23 Parkinson's disease 29 1.381536755 
24 Progesterone-mediated oocyte maturation 89 1.343600254 
25 Insulin resistance 94 1.285414079 
26 Vasopressin-regulated water reabsorption 22 1.271153449 
27 HTLV-I infection 194 1.217230571 
28 Tight junction 125 1.212432605 
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29 Bladder cancer 29 1.203205273 
30 Inflammatory bowel disease (IBD) 48 1.148826083 
31 Leukocyte transendothelial migration 85 1.128676988 
32 
Epithelial cell signaling in Helicobacter 
pylori infection 37 1.109696624 
33 Insulin signaling pathway 139 1.055000849 
34 Adipocytokine signaling pathway 63 1.046300074 
35 Amyotrophic lateral sclerosis (ALS) 36 0.983800494 
36 GnRH signaling pathway 85 0.966264685 
37 Breast cancer 143 0.943208322 
38 Oocyte meiosis 120 0.927522712 
39 Adherens junction 71 0.904756923 
40 Long-term potentiation 67 0.873254968 
41 Axon guidance 167 0.867502498 
42 Cytosolic DNA-sensing pathway 21 0.862616564 
43 ECM-receptor interaction 81 0.858243412 
44 Toll-like receptor signaling pathway 104 0.851435884 
45 Long-term depression 59 0.834863053 
46 alpha-Linolenic acid metabolism 25 0.815135135 
47 Pancreatic cancer 65 0.80634025 
48 Gap junction 88 0.799606955 
49 
Signaling pathways regulating pluripotency 
of stem cells 112 0.783109171 
50 Alzheimer's disease 48 0.771233168 
Table 3.13. Top 50 pathways ranked by T score comparing normal with hepatitis C-
induced HCC samples based on the Pearson’s correlation cutoff (-0.2). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 5.046943443 
2 Rap1 signaling pathway 208 4.065776968 
3 Hedgehog signaling pathway 47 3.836894713 
4 Cocaine addiction 42 2.779786983 
5 Circadian rhythm 31 2.594256419 
6 Wnt signaling pathway 137 2.398017415 
7 Hippo signaling pathway -multiple species 29 2.342737659 
8 RNA degradation 18 1.950279181 
9 Renal cell carcinoma 57 1.911332385 
10 Notch signaling pathway 48 1.888855572 
11 Vascular smooth muscle contraction 114 1.796469051 
12 
AGE-RAGE signaling pathway in diabetic 
complications 91 1.74328513 
13 Shigellosis 51 1.741513343 
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14 MAPK signaling pathway 252 1.720852339 
15 Bacterial invasion of epithelial cells 57 1.717291971 
16 Steroid biosynthesis 20 1.622392948 
17 mTOR signaling pathway 144 1.618051267 
18 Estrogen signaling pathway 89 1.608441789 
19 Thyroid cancer 28 1.606872903 
20 Dorso-ventral axis formation 13 1.57348981 
21 Calcium signaling pathway 179 1.532591743 
22 MicroRNAs in cancer 262 1.506902683 
23 Parkinson's disease 29 1.381536755 
24 Progesterone-mediated oocyte maturation 89 1.343600254 
25 Insulin resistance 94 1.285414079 
26 Vasopressin-regulated water reabsorption 22 1.271153449 
27 HTLV-I infection 194 1.217230571 
28 Tight junction 125 1.212432605 
29 Bladder cancer 29 1.203205273 
30 Inflammatory bowel disease (IBD) 48 1.148826083 
31 Leukocyte transendothelial migration 85 1.128676988 
32 
Epithelial cell signaling in Helicobacter pylori 
infection 37 1.109696624 
33 Insulin signaling pathway 139 1.055000849 
34 Adipocytokine signaling pathway 63 1.046300074 
35 Amyotrophic lateral sclerosis (ALS) 36 0.983800494 
36 GnRH signaling pathway 85 0.966264685 
37 Breast cancer 143 0.943208322 
38 Oocyte meiosis 120 0.927522712 
39 Adherens junction 71 0.904756923 
40 Long-term potentiation 67 0.873254968 
41 Axon guidance 167 0.867502498 
42 Cytosolic DNA-sensing pathway 21 0.862616564 
43 ECM-receptor interaction 81 0.858243412 
44 Toll-like receptor signaling pathway 104 0.851435884 
45 Long-term depression 59 0.834863053 
46 alpha-Linolenic acid metabolism 25 0.815135135 
47 Pancreatic cancer 65 0.80634025 
48 Gap junction 88 0.799606955 
49 
Signaling pathways regulating pluripotency of 
stem cells 112 0.783109171 
50 Alzheimer's disease 48 0.771233168 
Table 3.14. Top 50 pathways ranked by T score comparing normal with hepatitis C-
induced HCC samples based on the Pearson’s correlation cutoff (-0.1). 
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Gene 
Count(L) T score 
1 FoxO signaling pathway 126 3.81448289 
2 Cocaine addiction 42 3.622146675 
3 Hedgehog signaling pathway 47 3.071150497 
4 Rap1 signaling pathway 208 2.442721359 
5 Circadian rhythm 31 2.426885037 
6 Fatty acid biosynthesis 13 2.385487428 
7 Estrogen signaling pathway 89 2.363686878 
8 RNA degradation 18 2.22115129 
9 Calcium signaling pathway 179 2.059235544 
10 Hippo signaling pathway -multiple species 29 2.051175853 
11 Notch signaling pathway 48 1.829828835 
12 Glutamatergic synapse 89 1.820659046 
13 Morphine addiction 54 1.665147311 
14 alpha-Linolenic acid metabolism 25 1.63027027 
15 Vascular smooth muscle contraction 114 1.617006058 
16 Retrograde endocannabinoid signaling 59 1.578841462 
17 Shigellosis 51 1.551530069 
18 Wnt signaling pathway 137 1.539779604 
19 MAPK signaling pathway 252 1.457294704 
20 Pancreatic secretion 30 1.382495611 
21 Long-term depression 59 1.379338958 
22 Vasopressin-regulated water reabsorption 22 1.345927182 
23 HTLV-I infection 194 1.327880745 
24 Insulin resistance 94 1.325244579 
25 GABAergic synapse 66 1.285849245 
26 mTOR signaling pathway 144 1.245297312 
27 Thyroid hormone synthesis 46 1.22254989 
28 Huntington's disease 27 1.195229442 
29 Bacterial invasion of epithelial cells 57 1.132681938 
30 Maturity onset diabetes of the young 24 1.101228136 
31 Circadian entrainment 96 1.053790085 
32 MicroRNAs in cancer 262 1.053638972 
33 Gap junction 88 1.028066085 
34 Inflammatory bowel disease (IBD) 48 1.00344928 
35 Progesterone-mediated oocyte maturation 89 0.983890456 
36 
AGE-RAGE signaling pathway in diabetic 
complications 91 0.972996351 
37 GnRH signaling pathway 85 0.925147039 
38 Long-term potentiation 67 0.894620948 
39 Dopaminergic synapse 124 0.893777542 
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40 
Epithelial cell signaling in Helicobacter 
pylori infection 37 0.880104219 
41 Oocyte meiosis 120 0.879957445 
42 Chagas disease (American trypanosomiasis) 89 0.836077118 
43 Aldosterone synthesis and secretion 65 0.82394993 
44 Toll-like receptor signaling pathway 104 0.821858671 
45 Melanogenesis 101 0.820322345 
46 Alzheimer's disease 48 0.807137423 
47 Insulin secretion 54 0.792002705 
48 Renal cell carcinoma 57 0.790896159 
49 Transcriptional misregulation in cancer 19 0.789473684 
50 Valine, leucine and isoleucine degradation 48 0.783476417 
Table 3.15. Top 50 pathways ranked by T score comparing normal with alcohol-
induced HCC samples based on the Pearson’s correlation cutoff (-0.3). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 6.253538533 
2 Cocaine addiction 42 5.222630089 
3 Hedgehog signaling pathway 47 4.694720306 
4 Rap1 signaling pathway 208 3.85374078 
5 Circadian rhythm 31 3.682170401 
6 Estrogen signaling pathway 89 3.520828277 
7 Calcium signaling pathway 179 3.367955103 
8 Hippo signaling pathway -multiple species 29 3.270793928 
9 RNA degradation 18 2.762895507 
10 Glutamatergic synapse 89 2.68307649 
11 Wnt signaling pathway 137 2.650440301 
12 alpha-Linolenic acid metabolism 25 2.445405405 
13 Notch signaling pathway 48 2.420096201 
14 Morphine addiction 54 2.417885137 
15 Shigellosis 51 2.406454801 
16 Retrograde endocannabinoid signaling 59 2.395483597 
17 Fatty acid biosynthesis 13 2.385487428 
18 Vascular smooth muscle contraction 114 2.382841389 
19 Dorso-ventral axis formation 13 2.202885734 
20 Pancreatic secretion 30 2.172493102 
21 Long-term depression 59 2.141605224 
22 MAPK signaling pathway 252 2.141135101 
23 Renal cell carcinoma 57 2.109056425 
24 Vasopressin-regulated water reabsorption 22 2.093664505 
25 
AGE-RAGE signaling pathway in diabetic 
complications 91 2.027075732 
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26 Insulin resistance 94 1.980597638 
27 HTLV-I infection 194 1.959119287 
28 mTOR signaling pathway 144 1.939310767 
29 Huntington's disease 27 1.930755252 
30 Thyroid hormone synthesis 46 1.828730001 
31 GABAergic synapse 66 1.807643141 
32 GnRH signaling pathway 85 1.685823494 
33 Bacterial invasion of epithelial cells 57 1.680753844 
34 Maturity onset diabetes of the young 24 1.651842204 
35 Circadian entrainment 96 1.580685128 
36 Gap junction 88 1.580175649 
37 Progesterone-mediated oocyte maturation 89 1.551298787 
38 
Epithelial cell signaling in Helicobacter 
pylori infection 37 1.492350632 
39 MicroRNAs in cancer 262 1.491486361 
40 Salmonella infection 72 1.453479831 
41 Long-term potentiation 67 1.426557728 
42 Toll-like receptor signaling pathway 104 1.41340293 
43 Insulin signaling pathway 139 1.360570584 
44 Tight junction 125 1.350305952 
45 Dopaminergic synapse 124 1.329235264 
46 Oocyte meiosis 120 1.308044851 
47 Inflammatory bowel disease (IBD) 48 1.294202886 
48 Melanogenesis 101 1.282685848 
49 
Inflammatory mediator regulation of TRP 
channels 91 1.258568268 
50 Insulin secretion 54 1.257426218 
Table 3.16. Top 50 pathways ranked by T score comparing normal with alcohol-
induced HCC samples based on the Pearson’s correlation cutoff (-0.2). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 6.253538533 
2 Cocaine addiction 42 
5.22263008
9 
3 Hedgehog signaling pathway 47 
4.69472030
6 
4 Rap1 signaling pathway 208 3.85374078 
5 Circadian rhythm 31 3.682170401 
6 Estrogen signaling pathway 89 3.520828277 
7 Calcium signaling pathway 179 3.367955103 
8 Hippo signaling pathway -multiple species 29 3.270793928 
9 RNA degradation 18 2.762895507 
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10 Glutamatergic synapse 89 2.68307649 
11 Wnt signaling pathway 137 2.650440301 
12 alpha-Linolenic acid metabolism 25 2.445405405 
13 Notch signaling pathway 48 2.420096201 
14 Morphine addiction 54 2.417885137 
15 Shigellosis 51 2.406454801 
16 Retrograde endocannabinoid signaling 59 2.395483597 
17 Fatty acid biosynthesis 13 2.385487428 
18 Vascular smooth muscle contraction 114 2.382841389 
19 Dorso-ventral axis formation 13 2.202885734 
20 Pancreatic secretion 30 2.172493102 
21 Long-term depression 59 2.141605224 
22 MAPK signaling pathway 252 2.141135101 
23 Renal cell carcinoma 57 2.109056425 
24 Vasopressin-regulated water reabsorption 22 
2.09366450
5 
25 
AGE-RAGE signaling pathway in diabetic 
complications 91 2.027075732 
26 Insulin resistance 94 1.980597638 
27 HTLV-I infection 194 1.959119287 
28 mTOR signaling pathway 144 1.939310767 
29 Huntington's disease 27 1.930755252 
30 Thyroid hormone synthesis 46 1.828730001 
31 GABAergic synapse 66 1.807643141 
32 GnRH signaling pathway 85 1.685823494 
33 Bacterial invasion of epithelial cells 57 1.680753844 
34 Maturity onset diabetes of the young 24 1.651842204 
35 Circadian entrainment 96 1.580685128 
36 Gap junction 88 1.580175649 
37 Progesterone-mediated oocyte maturation 89 1.551298787 
38 
Epithelial cell signaling in Helicobacter 
pylori infection 37 1.492350632 
39 MicroRNAs in cancer 262 1.491486361 
40 Salmonella infection 72 1.453479831 
41 Long-term potentiation 67 1.426557728 
42 Toll-like receptor signaling pathway 104 1.41340293 
43 Insulin signaling pathway 139 1.360570584 
44 Tight junction 125 1.350305952 
45 Dopaminergic synapse 124 1.329235264 
46 Oocyte meiosis 120 1.308044851 
47 Inflammatory bowel disease (IBD) 48 1.294202886 
48 Melanogenesis 101 1.282685848 
49 
Inflammatory mediator regulation of TRP 
channels 91 1.258568268 
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50 Insulin secretion 54 1.257426218 
Table 3.17. Top 50 pathways ranked by T score comparing normal with alcohol-induced 
HCC samples based on the Pearson’s correlation cutoff (-0.1). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 0.285933 
2 RNA degradation 18 0.270872 
3 Bladder cancer 29 0.133689 
4 MicroRNAs in cancer 262 0.111402 
5 Hedgehog signaling pathway 47 0.107228 
6 Circadian rhythm 31 0.083686 
7 Amyotrophic lateral sclerosis (ALS) 36 0.081983 
8 Platinum drug resistance 41 0.080392 
9 p53 signaling pathway 68 0.066399 
10 Shigellosis 51 0.063328 
11 Phototransduction 27 0.062432 
12 Cell cycle 124 0.057685 
13 Hippo signaling pathway -multiple species 29 0.055437 
14 Transcriptional misregulation in cancer 19 0.052632 
15 Pancreatic cancer 65 0.047432 
16 HTLV-I infection 194 0.041036 
17 
AGE-RAGE signaling pathway in diabetic 
complications 91 0.040542 
18 Bacterial invasion of epithelial cells 57 0.036538 
19 Small cell lung cancer 83 0.03451 
20 Pathogenic Escherichia coli infection 40 0.03419 
21 Hepatitis B 134 0.033589 
22 Phagosome 32 0.033142 
23 HIF-1 signaling pathway 102 0.032685 
24 Galactose metabolism 28 0.032464 
25 Salmonella infection 72 0.0323 
26 Chronic myeloid leukemia 73 0.032277 
27 Breast cancer 143 0.032064 
28 EGFR tyrosine kinase inhibitor resistance 81 0.029106 
29 Non-small cell lung cancer 54 0.02828 
30 Glioma 66 0.028163 
31 Melanoma 69 0.027454 
32 Starch and sucrose metabolism 36 0.026393 
33 PI3K-Akt signaling pathway 340 0.026082 
34 Adipocytokine signaling pathway 63 0.02552 
35 Wnt signaling pathway 137 0.025242 
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36 Sphingolipid metabolism 47 0.02522 
37 Oocyte meiosis 120 0.023783 
38 Insulin signaling pathway 139 0.022193 
39 Progesterone-mediated oocyte maturation 89 0.021561 
40 Apoptosis 133 0.020906 
41 Tuberculosis 173 0.019046 
42 Gap junction 88 0.019038 
43 Insulin resistance 94 0.01884 
44 Pathways in cancer 310 0.018686 
45 Protein processing in endoplasmic reticulum 51 0.018554 
46 MAPK signaling pathway 252 0.017528 
47 Glycerophospholipid metabolism 94 0.017197 
48 NF-kappa B signaling pathway 81 0.017163 
49 Central carbon metabolism in cancer 63 0.017052 
50 Leukocyte transendothelial migration 85 0.016573 
Table 3.18. Top 50 pathways ranked by T score comparing normal with HCC samples 
based on the Pearson’s correlation cutoff (-0.4). 
 
  
Gene 
Count(L) T score 
1 FoxO signaling pathway 126 1.366805 
2 Hedgehog signaling pathway 47 1.141043 
3 Circadian rhythm 31 1.087914 
4 Dorso-ventral axis formation 13 0.786745 
5 Rap1 signaling pathway 208 0.666197 
6 Wnt signaling pathway 137 0.6563 
7 RNA degradation 18 0.650093 
8 Oxidative phosphorylation 47 0.619513 
9 Renal cell carcinoma 57 0.593172 
10 Bladder cancer 29 0.534758 
11 Ribosome biogenesis in eukaryotes 3 
0.48648
6 
12 Shigellosis 51 0.474958 
13 Toll-like receptor signaling pathway 104 0.473235 
14 MAPK signaling pathway 252 0.472747 
15 HTLV-I infection 194 0.463854 
16 GnRH signaling pathway 85 0.411176 
17 Amyotrophic lateral sclerosis (ALS) 36 0.409917 
18 MicroRNAs in cancer 262 0.389905 
19 Hippo signaling pathway -multiple species 29 0.38806 
20 Vasopressin-regulated water reabsorption 22 0.373869 
21 Estrogen signaling pathway 89 0.369246 
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22 Parkinson's disease 29 0.345384 
23 Fatty acid biosynthesis 13 0.340784 
24 Sphingolipid metabolism 47 0.327862 
25 
AGE-RAGE signaling pathway in diabetic 
complications 91 0.324332 
26 Salmonella infection 72 0.322996 
27 Viral carcinogenesis 6 0.31982 
28 Legionellosis 40 0.316216 
29 
Epithelial cell signaling in Helicobacter pylori 
infection 37 0.306123 
30 Platinum drug resistance 41 0.294772 
31 Sulfur metabolism 9 0.292762 
32 Bacterial invasion of epithelial cells 57 0.292305 
33 Antigen processing and presentation 62 0.273428 
34 Thyroid cancer 28 0.2571 
35 Cocaine addiction 42 0.252708 
36 Notch signaling pathway 48 0.236107 
37 RIG-I-like receptor signaling pathway 48 0.22424 
38 Insulin signaling pathway 139 0.221931 
39 Regulation of autophagy 19 0.217501 
40 Nitrogen metabolism 4 0.2173 
41 TNF signaling pathway 72 
0.20428
4 
42 Inflammatory mediator regulation of TRP channels 91 0.202757 
43 Adherens junction 71 0.196686 
44 Fc epsilon RI signaling pathway 61 0.195855 
45 Thyroid hormone synthesis 46 0.19357 
46 Pyrimidine metabolism 105 0.188895 
47 p53 signaling pathway 68 0.185916 
48 Vascular smooth muscle contraction 114 0.182394 
49 Tuberculosis 173 0.180941 
50 HIF-1 signaling pathway 102 0.179767 
Table 3.19. Top 50 pathways ranked by T score comparing normal with hepatitis B-
induced HCC samples based on the Pearson’s correlation cutoff (-0.4). 
 
  
Gene 
Count(L) T score 
1 Hedgehog signaling pathway 47 0.589755 
2 RNA degradation 18 0.433395 
3 Bladder cancer 29 0.401068 
4 FoxO signaling pathway 126 0.366039 
5 Fatty acid biosynthesis 13 0.340784 
6 Circadian rhythm 31 0.334743 
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7 Lipoic acid metabolism 3 0.303191 
8 Steroid biosynthesis 20 
0.28402
6 
9 Porphyrin and chlorophyll metabolism 39 0.26793 
10 Homologous recombination 18 0.241308 
11 Nitrogen metabolism 4 0.2173 
12 Shigellosis 51 0.189983 
13 Parkinson's disease 29 0.172692 
14 Amyotrophic lateral sclerosis (ALS) 36 0.163967 
15 Rap1 signaling pathway 208 0.158618 
16 MicroRNAs in cancer 262 0.153177 
17 Wnt signaling pathway 137 0.151454 
18 Sulfur metabolism 9 0.146381 
19 Platinum drug resistance 41 0.133987 
20 Drug metabolism - cytochrome P450 70 0.13375 
21 Fanconi anemia pathway 40 0.133169 
22 Butanoate metabolism 27 0.114959 
23 Viral myocarditis 26 0.113768 
24 Hippo signaling pathway -multiple species 29 0.110874 
25 Valine, leucine and isoleucine degradation 48 0.109783 
26 Bacterial invasion of epithelial cells 57 0.109614 
27 Legionellosis 40 0.105405 
28 Pathogenic Escherichia coli infection 40 0.10257 
29 Sphingolipid metabolism 47 0.100881 
30 Cell cycle 124 0.096141 
31 Fatty acid degradation 42 0.092897 
32 Vascular smooth muscle contraction 114 0.091197 
33 MAPK signaling pathway 252 0.087642 
34 Ascorbate and aldarate metabolism 21 0.084129 
35 Lysine degradation 55 0.082721 
36 
AGE-RAGE signaling pathway in diabetic 
complications 91 0.081083 
37 TGF-beta signaling pathway 73 
0.08069
2 
38 p53 signaling pathway 68 0.079678 
39 
Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 10 0.077027 
40 Tuberculosis 173 0.076186 
41 Folate biosynthesis 14 0.071429 
42 Pancreatic cancer 65 0.071148 
43 HTLV-I infection 194 0.068393 
44 Phagosome 32 
0.06628
4 
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45 Renal cell carcinoma 57 
0.06590
8 
46 Natural killer cell mediated cytotoxicity 134 0.064933 
47 Salmonella infection 72 0.064599 
48 Colorectal cancer 49 0.064341 
49 Thyroid cancer 28 0.064275 
50 Breast cancer 143 0.064129 
Table 3.20. Top 50 pathways ranked by T score comparing normal with hepatitis C-
induced HCC samples based on the Pearson’s correlation cutoff (-0.4). 
 
  
Gene 
Count(L) T score 
1 Fatty acid biosynthesis 13 0.340784 
2 RNA degradation 18 0.270872 
3 FoxO signaling pathway 126 0.21445 
4 Bladder cancer 29 0.133689 
5 Phototransduction 27 0.124864 
6 Hedgehog signaling pathway 47 0.107228 
7 Circadian rhythm 31 0.083686 
8 Amyotrophic lateral sclerosis (ALS) 36 0.081983 
9 Platinum drug resistance 41 0.080392 
10 Shigellosis 51 0.063328 
11 MicroRNAs in cancer 262 0.055701 
12 Hippo signaling pathway -multiple species 29 0.055437 
13 Propanoate metabolism 32 0.053321 
14 
AGE-RAGE signaling pathway in diabetic 
complications 91 0.040542 
15 Bacterial invasion of epithelial cells 57 0.036538 
16 Pathogenic Escherichia coli infection 40 0.03419 
17 Phagosome 32 0.033142 
18 HIF-1 signaling pathway 102 0.032685 
19 Salmonella infection 72 0.0323 
20 EGFR tyrosine kinase inhibitor resistance 81 0.029106 
21 HTLV-I infection 194 0.027357 
22 Wnt signaling pathway 137 0.025242 
23 Sphingolipid metabolism 47 0.02522 
24 Pyruvate metabolism 39 0.023651 
25 Insulin signaling pathway 139 0.022193 
26 Apoptosis 133 
0.02090
6 
27 Cell cycle 124 0.019228 
28 Tuberculosis 173 0.019046 
29 Protein processing in endoplasmic reticulum 51 0.018554 
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30 MAPK signaling pathway 252 0.017528 
31 NF-kappa B signaling pathway 81 0.017163 
32 Central carbon metabolism in cancer 63 0.017052 
33 Natural killer cell mediated cytotoxicity 134 0.016233 
34 Colorectal cancer 49 0.016085 
35 RNA transport 133 0.015116 
36 AMPK signaling pathway 97 0.014694 
37 PI3K-Akt signaling pathway 340 0.01449 
38 Hepatitis C 97 0.014287 
39 Endocrine resistance 95 0.013688 
40 Hepatitis B 134 0.013436 
41 p53 signaling pathway 68 0.01328 
42 Glucagon signaling pathway 86 0.013129 
43 Chronic myeloid leukemia 73 0.012911 
44 TNF signaling pathway 72 0.012768 
45 Circadian entrainment 96 0.012545 
46 Oocyte meiosis 120 0.011891 
47 Pancreatic cancer 65 0.011858 
48 Prostate cancer 87 0.010359 
49 Pathways in cancer 310 0.009343 
50 Hippo signaling pathway 151 0.009231 
Table 3.21. Top 50 pathways ranked by T score comparing normal with alcohol-
induced HCC samples based on the Pearson’s correlation cutoff (-0.4). 
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Chapter 4: Conclusion, Discussion and Next Steps 
Complex diseases such as cancer are usually result from a combination of environmental 
factors and one or several biological pathways consisting of sets of genes. Each biological 
pathways exerts its own function by delivering signaling through the gene network. The 
interactions and reactions of genes and their products constitute a biological pathway. 
The activation and inhibition of biological pathways directly influence on the onset and 
development of complex diseases. Hence, it is fairly important to detect disease-related 
biological pathways. 
A biological pathway might be influenced by some aberrant genes in this pathway or 
some aberrant regulators, such as miRNAs, that regulate this pathway. In this 
dissertation, we investigate how these two layers of components, genes and miRNAs, 
cause the aberration of biological pathways. 
It is well known that aberrantly expressed genes in the pathway and/or aberrantly 
expressed miRNAs regulating the pathways can trigger dysregulation of the biological 
pathways. There are many studies on this area. The interplay of genes, miRNAs and 
biological pathways has been increasing active over the past decade. Some methods have 
been created to identify functional networks across different phenotypes from changes in 
gene expression, as well as some methods have been created to identify miRNA 
regulatory networks across different phenotypes from changes in miRNA expression. On 
the other hand, altered gene-gene connections in biological pathways and/or altered 
miRNA-mRNA connections might also impact the activity of biological pathways. In this 
dissertation, we discuss how these altered gene-gene connections (Chapter 1) and altered 
miRNA-mRNA connections (Chapter 2) aberrantly influence the activity of biological 
pathways and their association with disease. 
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In Chapter 1, we propose a method called PoTRA, Pathways of Topological Rank 
Analysis, to detect pathways involved in cancer. PoTRA is motivated by that the loss of 
connectivity is a common topological trait of cancer networks, and the prior knowledge 
that a normal biological network is a scale-free network whose degree distribution 
follows a power law where a small number of nodes are hubs and a large number of 
nodes are non-hubs. From normal to cancer state, the process of the network losing 
connectivity could be the process of disrupting the scale-free structure of the network, 
that is to say, the number of hub genes might be altered in cancer compared to that in 
normal samples. Hence, it is hypothesized that if the number of hub genes is different in 
a pathway between normal and cancer, this pathway might be involved in cancer. Based 
on this hypothesis, we propose to detect pathways involved in cancer by testing the 
pathways with altered number of hub genes between normal and cancer samples. 
Thus, the PoTRA method focuses on topological ranks of genes in each pathway, so we 
use the Google search PageRank algorithm to compute the relative topological ranks of 
genes in each pathway across different phenotypes, and then select the hub genes for 
each pathway, then detects pathways with significantly altered number of hub genes 
between normal and cancer samples. For the testing step, we use Fisher’s exact test to 
estimate if the number of hub genes in each pathway is altered between normal and 
cancer. We apply PoTRA to HCC and three subtypes of HCC (hepatitis B, hepatitis C, 
alcohol). We discover many HCC-relevant pathways generally and HCC subtype-relevant 
pathways specifically.  
In Chapter 2, we propose a new PageRank-based method, called miR2Pathway, to 
quantifying the differential effects of miRNAs on the activity of a biological pathway and 
rank disease risk of rewired miRNA-mediated biological pathways. It is motivated that a 
miRNA might differentially regulate genes between normal and cancer, and these 
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differential regulations could aberrantly influence activity of biological pathways. 
Namely, there are two cases. In case 1, a miRNA might regulate several genes in normal 
tissue, while this miRNA might lose these regulatory connections in cancer tissue; in case 
2, this miRNA regulates the same number of non-hub genes in this pathway in normal 
tissue, while it loses the regulatory connections in tumor tissue. Our hypothesis is that 
this miRNA has a larger differential influence on the activity of the pathway in case 1 
than case 2. We use PageRank to compute the topological influence (PageRank scores) of 
the targeted genes in this differential network, which quantifies the topological influence 
of the genes that are differentially targeted by a miRNA on the activity of this pathway. 
Then we can compute the sum of PageRank scores of genes targeted by the miRNA in the 
differential network, which estimates the total differential influence of a miRNA on the 
activity of this pathway. Then, the same procedure is repeated for all miRNAs, so that we 
can obtain a corresponding sum of PageRank scores for each miRNA. For a specific 
pathway, we estimate the total differential influence of all the miRNAs on this pathway 
through summing up all the sums corresponding to all the miRNAs. Namely, the total 
differential influence of all the miRNAs on this pathway reflects the degree of miRNA-
mediated dysregulation of this pathway. We do this for each pathway. Finally, we rank all 
the pathways by the degree of miRNA-mediated dysregulation scores. We apply 
miR2Pathway to HCC and the three subtypes of HCC. Very interestingly, we also 
discover many HCC-relevant pathways generally and HCC subtype-relevant pathways 
specifically.  
For PoTRA, the hypothesis of our study is based on the fact that the loss of connectivity 
is a common topological trait of cancer networks. However, we still cannot well 
understand if this trait is characteristic of other complex diseases. Hence, we have to be 
careful about the applicability of PoTRA to other diseases. Although PoTRA is motivated 
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by work on cancer, it could apply to other complex diseases as well. This direction needs 
to be further explored. For miR2Pathway, miR2Pathway is applied to pre-defined 
biological pathways, from the well-curated KEGG pathway database. To extend this 
application, we also can apply miR2Pathway to any set of genes of interest, such as 
functional gene networks. Additionally, miR2Pathway might also be used to estimate 
differential influence of other regulatory factors, e.g., transcriptional factors (TFs), on 
biological pathways. For another point, miR2Pathway is used to rank the degree of 
miRNA-mediated dysregulation in our study. It is seen that there is no cutoff in it. 
Therefore, how to set up the cutoff level will become an important and interesting 
direction to explore in the future. 
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